WO2006055511A2 - Stable tablet formulation of tetrahydrobiopterin - Google Patents

Stable tablet formulation of tetrahydrobiopterin Download PDF

Info

Publication number
WO2006055511A2
WO2006055511A2 PCT/US2005/041252 US2005041252W WO2006055511A2 WO 2006055511 A2 WO2006055511 A2 WO 2006055511A2 US 2005041252 W US2005041252 W US 2005041252W WO 2006055511 A2 WO2006055511 A2 WO 2006055511A2
Authority
WO
WIPO (PCT)
Prior art keywords
tablet formulation
stable tablet
tetrahydrobiopterin
stable
acid
Prior art date
Application number
PCT/US2005/041252
Other languages
French (fr)
Other versions
WO2006055511A3 (en
Inventor
Steven Jungles
Mark Henderson
Victoria Sluzky
Robert Baffi
Original Assignee
Biomarin Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35849290&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2006055511(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to MX2007005039A priority Critical patent/MX2007005039A/en
Priority to BRPI0517088-5A priority patent/BRPI0517088A/en
Priority to US10/563,418 priority patent/US8003126B2/en
Priority to AU2005306686A priority patent/AU2005306686B2/en
Priority to JP2007541419A priority patent/JP2008520574A/en
Application filed by Biomarin Pharmaceutical Inc. filed Critical Biomarin Pharmaceutical Inc.
Priority to CA2581814A priority patent/CA2581814C/en
Priority to EP05822282A priority patent/EP1845952A2/en
Publication of WO2006055511A2 publication Critical patent/WO2006055511A2/en
Publication of WO2006055511A3 publication Critical patent/WO2006055511A3/en
Priority to IL182161A priority patent/IL182161A/en
Priority to US12/106,621 priority patent/US7566462B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism

Definitions

  • the present invention is generally directed to stable tablet formulations of tetrahydrobiopterin or precursors, derivatives or analogs thereof for the treatment of humans.
  • Tetrahydrobiopterin (sometimes referred to as BH4) is a biogenic amine of the naturally-occurring pterin family that is a cofactor for a number of different enzymes, including phenylalanine hydroxylase (PAH), tyrosine hydroxylase, tryptophan hydroxylase and nitric oxide synthase.
  • Pterins are present in physiological fluids and tissues in reduced and oxidized forms, however, only the 5,6,7,8, tetrahydrobiopterin is biologically active. It is a chiral molecule and the 6R enantiomer of the cofactor is known to be the biologically active enantiomer.
  • a deficiency in PAH activity due to absent or mutated PAH enzyme or a deficiency in its cofactor BH4, manifests as an excess of the amino acid phenylalanine (Phe) known as hyperphenylalaninemia (HPA) in its very mildest forms or phenylketonuria (PKU) in its moderate or severe forms.
  • Phe amino acid phenylalanine
  • HPA hyperphenylalaninemia
  • PKU phenylketonuria
  • PAH deficiency also causes a deficiency in the amino acid tyrosine, which is a precursor for synthesis of neurotransmitters.
  • a deficiency in tyrosine hydroxylase or tryptophan hydroxylase activity can manifest as a deficiency in neurotransmitter production.
  • tetrahydrobiopterin products available on the market need to be specially packaged or kept frozen.
  • the labeling on the tablets sold by Schirck's Laboratory specify that the tablets should be kept frozen and state that the product has a shelf life at room temperature of only 2 months.
  • BIOPTEN tetrahydrobiopterin granules
  • BIOPTEN requires expensive, hermetically-sealed foil packaging to maintain room temperature stability. The instability of such BH4 compositions is commercially undesirable and significant degradation due to improper storage could hinder therapy of patients.
  • Drug substance polymorphic forms can exhibit different physical and mechanical properties, including hygroscopicity, particle shape, density, flowability, and compactibility, which in turn may affect processing of the drug substance and/or manufacturing of the drug product.
  • the effect of polymorphism on pharmaceutical processing also depends on the formulation and the manufacturing process.
  • Polymorphic forms of the drug substance can undergo phase conversion when exposed t ⁇ a range of manufacturing processes, such as drying, milling, micronization, wet granulation, spray-drying, and compaction. Exposure to environmental conditions such as humidity and temperature can also induce polymorph conversion. The extent of conversion generally depends on the relative stability of the polymorphs, kinetic barriers for phase conversion, and applied stress.
  • the present invention relates to stable solid formulations of tetrahydrobiopterin, particularly stable tablets, processes for producing such formulations, and treatment methods using such formulations.
  • compositions of the invention may comprise a stable, crystalline form of BH4 that is stable at room temperature for more than 8 hours and a pharmaceutically acceptable carrier, diluent or excipient.
  • Exemplary stable tablets of the invention have been prepared using a dry tableting process and have been shown to have a shelf-life of at least 6 to 9 months at room temperature.
  • Another aspect of the invention provides a dry formulation process for preparing stable solid formulations, which includes the step of mixing tetrahydrobiopterin, or a precursor or derivative or analog thereof, with another pharmaceutical carrier, diluent or excipient, in the absence of added water.
  • the active pharmaceutical ingredient and excipients are dry blended and compressed.
  • the tablets are processed in humidity- controlled rooms where humidity is kept at about 65% (+ 5%) or less. Once processed, the tablets are stored in triple plastic lined water resistant containers with desiccant pillows lined between the outer two layers of plastic bags.
  • the invention includes a dry formulation method comprising the steps of mixing an initial amount of a crystalline polymorph of (6R)-L-erythro-tetrahydrobiopterin, preferably polymorph B, and one or more pharmaceutically acceptable excipients, and forming a tablet from the mixture, wherein the steps do not include adding liquid water.
  • Exemplary particle sizes include, e.g., from about 0.2 ⁇ m to about 500 ⁇ m, from about 1 ⁇ m to about 250 ⁇ m, or from about 2 ⁇ m to about 200 ⁇ m, or, e.g., larger than about 500 ⁇ m, larger than about 600 ⁇ m, larger than about 700 ⁇ m, or smaller than about 850 ⁇ m.
  • the tablet is initially manufactured using a stable crystalline form of (6R)-5,6,7,8-tetrahydrobiopterin described below as "polymorph B,” and retains at least about 95% of the active pharmaceutical ingredient (API) at room temperature after 3 months, 6 months or 9 months, or preferably 12 months or longer, e.g.
  • the tablet retains at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.5% of the API after storage at room temperature for such time periods.
  • the tablet also preferably exhibits loss on drying of 2% or less, or 1.5% or less, or 1% or less, or 0.9% or less, or 0.8% or less, or 0.7% or less, or 0.6% or less, after such time periods.
  • Exemplary tablets may be manufactured wherein the initial amount of tetrahydrobiopterin active pharmaceutical ingredient is about 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg or higher doses.
  • Preferred tablets also exhibit rapid disintegration upon administration, e.g., 3 minutes or less, to improve ease of administration.
  • the invention provides a stable tablet formulation comprising an initial amount of a crystalline polymorph, designated polymorph B, of (6R)-L- erythro-tetrahydrobiopterin and a pharmaceutically acceptable excipient, wherein after six months at room temperature and about 60% humidity the stable tablet formulation retains at least about 95% of the initial amount of ( ⁇ R)-L-erythro- tetrahydrobiopterin, and wherein said crystalline polymorph, as a hydrochloride salt, exhibits an X-ray powder diffraction pattern with the following characteristic peaks expressed in d-values(A) : 8.7 (vs), 5.63 (m), 4.76(m), 4.40 (m), 4.00 (s), 3.23 (s), 3.11 (vs), preferably 8.7 (vs), 6.9 (w), 5.90 (vw), 5.63 (m), 5.07 (m), 4.76 (m), 4.40 (m), 4.15 (w), 4.00 (s), 3.95 (m), 3.52 (m), 3.44 (w), 3.32
  • the tablet retains at least about 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.5% of the initial amount of (6R)-L- erythro-tetrahydrobiopterin.
  • the stable solid formulation preferably contains one or more of the following additional ingredients that improve stability or other characteristics of the formulation: binder, disintegrant, acidic antioxidant, or lubricant or combinations thereof.
  • binder disintegrant
  • acidic antioxidant or lubricant or combinations thereof.
  • One exemplary preferred composition includes anhydrous dibasic calcium phosphate, crospovidone, ascorbic acid and stearyl fumarate, optionally with mannitol and riboflavin.
  • the stable solid formulation may optionally include other therapeutic agents suitable for the condition to be treated, e.g.
  • folates including folate precursors, folic acids, or folate derivatives; and/or vitamins such as vitamin C and/or vitamin B 12; and/or neurotransmitter precursors such as L-dopa or carbidopa; and/or 5- hydroxytryptophan; and/or arginine.
  • Compositions comprising tetrahydrobiopterin (or a precursor or derivative or analog) and a folate, and optionally further comprising arginine, are particularly contemplated.
  • the invention further contemplates other stable solid formulations for oral administration, e.g. capsules, pills or troches, with similar stability properties.
  • Yet another aspect of the invention provides treatment methods using such stable solid formulations.
  • the invention contemplates that such formulations of the invention are useful for intervention in metabolic disorders, particularly those involving amino acid metabolism.
  • the stable formulations may be used for the treatment of subjects exhibiting elevated phenylalanine levels or decreased tyrosine levels, for example, subjects suffering from hyperphenylalanemia, mild phenylketonuria or classic severe phenylketonuria: and tor the treatment of subjects suffering from conditions that would benefit frovi enhancement of nitric oxide synthase activity, including vascular diseases, ischemic or inflammatory diseases, diabetes, or insulin resistance.
  • the total dose required for each treatment may be administered in multiple doses or in a single dose.
  • the stable formulations may be administered daily or at some other interval, e.g., every alternative day or even weekly.
  • the stable formulations may be used alone or in conjunction with other therapies suitable for the disorder to be treated, including the underlying disease or the clinical symptoms.
  • the stable formulations of the invention may be administered in combination with a protein-restricted diet, e.g. where the subject is limited to about 600 mg or less, or about 300 mg or less of protein daily, optionally with supplemental amino acids, such as tyrosine, valine, isoleucine and leucine.
  • the stable formulations may also be administered in combination with folates, arginine, vitamins, or neurotransmitter precursors.
  • the stable formulations of the invention may be administered in conjunction with other therapeutic agents such as anti-hypertensive agents, anti-platelet agents, cholesterol-lowering agents, insulin or oral hypoglycemic agents.
  • Figure 1 shows a characteristic X-ray powder diffraction pattern for crystalline polymorph B of (6R)-5,6,7,8-tetrahydrobiopterin dihydrochloride.
  • the present invention provides a stable formulation that maintains a stable crystalline polymorph of the active ingredient.
  • An anhydrous polymorph of ( ⁇ R.)-5,6, 7,8-tetrahydrobiopterin dihydrochloride that is stable at room temperature to atmospheric oxygen and normal humidity, described below as polymorph B 1 has been identified.
  • polymorph B 1 when the percent relative humidity approaches 80%, polymorph B appears to take up much more water, loses its crystalline form, and becomes labile to oxidation.
  • Stable tablet formulations of the invention have been made using polymorph B in a dry formulation process and have been shown to retain 99% or more of the initial (6R)-5,6,7,8-tetrahydrobiopterin for at least 6 or 9 months, both at normal room temperature and humidity, and under accelerated testing conditions.
  • shelf life means the storage period during which an active pharmaceutical ingredient (API) in a pharmaceutical formulation has minimal degradation (e.g., not more than about 5% degradation) when the pharmaceutical formulation is stored under specified storage conditions, for example, room temperature at normal humidity.
  • API active pharmaceutical ingredient
  • the shelf-life of the stable formulations of the invention may be measured as follows.
  • the formulation to be tested may be divided into one or more different batches and stored under typical storage conditions, for example, 4 0 C (refrigerator), or 25 0 C (room temperature).
  • Degradation of the API in a pharmaceutical formulation can also be detected using accelerated testing under exaggerated storage conditions designed to increase the degradation rate of the drug substance. For example, a batch can be "stressed" (placed in chamber which maintains a temperature of 45 0 C and 75% humidity).
  • Samples of each batch of formulation are then analyzed at different time points (e.g., time zero,.2 weeks, 1 month, 3 months, 6 months, 9 months, 1 year, 1.5 years, 2-years, 2.5 years, 3 years or longer) for amount of API still present in the formulation.
  • Analysis of the API in the formulation may be carried out by a variety of detection methods including high performance liquid chromatography, crystal or powder X-ray diffraction, infrared or Raman spectra studies, microscopy, differential scanning calorimetry, thermal gravimetric analysis, hot-stage microscopy, and solid state nuclear magnetic resonance.
  • Maintenance of a particular polymorph form can be determined by carrying out, e.g., powder or crystal X-ray diffraction studies or any of the same techniques used to analyze the polymorph initially.
  • Nonlimiting examples of analogs for use in the compositions and methods described herein include pyridine, pterin, neopterin, biopterin, 7,8- Dihydrobiopterin, 6-methyltetrahydro ⁇ terin, and other 6-substituted tetrahydropterin and other 6-substituted tetrahydropterins, sepiapterin, 6,7-Dimethyltetrahydropterin, 6-methyl biopterin and other 6-substituted biopterins, and other analogs that are described in the art.
  • Nonlimiting examples of derivatives for use in the compositions and methods described herein include the derivatives described in U.S. Patent Nos.
  • the (6R) form of BH4 is the known biologically active form, however, BH4 is known to be unstable at ambient temperatures.
  • BH4 is difficult to handle and it was therefore produced and offered as its dihydrochloride salt (Schircks Laboratories, Jona, Switzerland) in ampoules sealed under nitrogen to prevent degradation of the substance due to its hygroscopic nature and sensitivity to oxidation.
  • U.S. Patent No. 4,649,197 discloses that separation of (6R)- and 6(S)-L-erythro-tetrahydrobiopterin dihydrochloride into its diastereomers is difficult due to the poor crystallinity of 6(R.S)-L-- ⁇ ythro-tetrahydrobiopterin dihydrochlcride.
  • the European patent number 0 079 574 describes the preparation of tetrahydrobiopterin, wherein a solid tetrahydrobiopterin dihydrochloride is obtained as an intermediate.
  • S. Matsuura et al. describes in Chemistry Letters 1984, pages 735- 738 and Heterocycles, Vol. 23, No. 12, 1985 pages 3115-3120 6(R)- tetrahydrobiopterin dihydrochloride as a crystalline solid in form of colorless needles, which are characterized by X-ray analysis disclosed in J. Biochem. 98, 1341-1348 (1985). An optical rotation of 6.81° was found the crystalline product, which is quite similar to the optical rotation of 6.51 ° reported for a crystalline solid in form of white crystals in example 6 of EP-A2-0 191 335.
  • Form B The crystal polymorph that has been found to be the most stable is referred to herein as "form B,” or alternatively as “polymorph B.”
  • Polymorph B is a slightly hygroscopic anhydrate with the highest thermodynamic stability above about 20 °C. Furthermore, form B can be easily processed and handled due to its thermal stability, possibility for preparation by targeted conditions, its suitable morphology and particle size. Melting point is near 260 0 C ( ⁇ Hf > 140 J/g), but no clear melting point can be detected due to decomposition prior and during melting. These outstanding properties renders polymorph form B especially feasible for pharmaceutical applications, which are often prepared at elevated temperatures. Polymorph B can be obtained as a fine powder with a particle size that may range from 0.2 ⁇ m to 500 ⁇ m.
  • Form B exhibits an X-ray powder diffraction pattern, expressed in d- values (A) at: 8.7 (vs), 6.9 (w), 5.90 (vw), 5.63 (m), 5.07 (m), 4.76 (m), 4.40 (m), 4.15 (w), 4.00 (s), 3.95 (m), 3.52 (m), 3.44 (w), 3.32 (m), 3.23 (s), 3.17 (w), 3.11 (vs), 3.06 ; w), 2.09 (w), 2.96 (w), 2.94 (m), 2.87 (w), 2.84 (s), 2.82 (m), 2.69 (w), 2.59 (w), 2.44 (w).
  • Figure 1 is a graph of the characteristic X-ray diffiaction pattern exhibited by form B of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride.
  • Form B can be prepared in very large quantities (e.g., 100 kilo scale) and stored over an extended period of time.
  • Crystal forms can be used for the preparation of the most stable polymorph B.
  • Polymorph B may be obtained by phase equilibration of suspensions of amorphous or other forms, in suitable polar and non aqueous solvents.
  • BH4 can be converted into form B by dispersing the other form of BH4 in a solvent at room temperature, stirring the suspension at ambient temperatures for a time sufficient to produce polymorph form B, thereafter isolating crystalline form B and removing the solvent from the isolated form B.
  • Ambient temperatures mean temperatures in a range from O °C to 60 0 C, preferably 15 0 C to 40 0 C.
  • the applied temperature may be changed during treatment and stirring by decreasing the temperature stepwise or continuously.
  • Suitable solvents for the conversion of other forms to form B include but are not limited to, methanol, ethanol, isopropanol, other C3- and C4-alcohols, acetic acid, acetonitrile, tetrahydrofurane, methy-t-butyl ether, 1 ,4-dioxane, ethyl acetate, isopropyl acetate, other C3-C6-acetates, methyl ethyl ketone and other methyl-C3-C5 alkyl -ketones.
  • the time to complete phase equilibration may be up to 30 hours and preferably up to 20 hours or less than 20 hours.
  • Polymorph B may also be obtained by crystallisation from solvent mixtures containing up to about 5% water, especially from mixtures of ethanol, acetic acid and water. It has been found that polymorph form B of (6R)-L-erythro- tetrahydrobiopterin dihydrochloride can be prepared by dissolution, optionally at elevated temperatures, preferably of a solid lower energy form than form B of of form B of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride in a solvent mixture comprising ethanol, acetic acid and water, addition of seeds to the solution, cooling the obtained suspension and isolation of the formed crystals. Dissolution may be carried out at room temperature or up to 70 0 C, preferably up to 50 0 C.
  • the composition of the solvent mixture may comprise a volume ratio of water : acetic acid : tetrahydrofuran of 1 : 3: 2 to 1 : 9: 4 and preferably 1 : 5: 4.
  • the solution is preferably stirred. Cooling may mean temperatures down to -40 °C to 0 °C, preferably down to 10 0 C to 30 0 C.
  • Suitable seeds are polymorph form B from another batch or crystals having a similar or identical morphology. After isolation, the crystalline form B can be washed with a non-solvent such as acetone or tetrahydrofurane and dried in usual manner.
  • Polymorph B may also be obtained by crystallization from aqueous solutions through the addition of non-solvents such as methanol, ethanol and acetic acid.
  • the crystallisation and isolation procedure can be advantageously carried out at room temperature without cooling the solution. This process is therefore very suitable to be carried out at an industrial scale.
  • a composition including polymorph form B of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride is prepared by dissolution of a solid form other than form B or of form B of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride in water at ambient temperatures, adding a non-solvent in an amount sufficient to form a suspension, optionally stirring the suspension for a certain time, and thereafter isolation of the formed crystals.
  • the composition is further modified into a pharmaceutical composition as described below.
  • the concentration of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride in the aqueous solution may be from 10 to 80 percent by weight, more preferably. from 20 to 60 percent by weight, by reference to the solution.
  • Preferred non-solvents i.e., solvents useful in preparing suspensions of BH4 are methanol, ethanol and acetic acid.
  • the non-solvent may be added to the aqueous solution. More preferably, the aqueous solution is added to the non-solvent.
  • the stirring time after formation of the suspension may be up to 30 hours and preferably up to 20 hours or les ⁇ than 20 hours. Isolation by filtration and drying u earned out in known manner as desz.nbsd above.
  • Polymorph form B is a very stable crystalline form, that can be easily filtered off, dried and ground to particle sizes desired for pharmaceutical formulations. These outstanding properties renders polymorph form B especially feasible for pharmaceutical application.
  • compositions may initially include a stable crystalline form of tetrahydrobiopterin, or a precursor or derivative or analog thereof, with a pharmaceutically acceptable carrier.
  • the stable formulation of the invention preferably contains one or more of the following additional ingredients that improve the stability or other characteristics of the formulation: binder, disintegration agent, acidic antioxidant, or lubricant or combinations thereof.
  • a stable tablet formulation includes a binder and disintegration agent, optionally with an acidic antioxidant, and optionally further including a lubricant.
  • the initial amount of a crystalline polymorph of (6R)-L-erythro- tetrahydrobiopterin used to prepare the formulation may be, for example, in the range of about 30 wt% to about 40 wt% of the formulation, or in the range of about 32 wt% to about 35 wt%, or at about 33 wt%.
  • Binders assist in maintaining the tablet formulation.
  • anhydrous binders are used to preserve the anhydrous state of polymorph B.
  • the binder may act as a drying agent.
  • Exemplary binders include anhydrous dibasic calcium phosphate and its monohydrate.
  • concentrations of the binder in a stable tablet formulation of the present invention are between about 1 wt% to about 5 wt%. Particularly contemplated concentrations are between about 1.5 and 3 wt%. Also contemplated are concentrations of binder of at least about 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, and 3.0 wt%, or concentrations up to about 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3. 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, and 5.0 wt%.
  • the weight ratio of binder to tetrahydrobiopte ⁇ n in a stable tablet formulation of the present invention is, for example, in the range of about 1 : 10 to about 1 :20. Also contemplated are weight ratios of abou ⁇ 1 : 10.25, 1:10.5, 1.10.75, 1 :11, 1 :11.25, 1 :1 1.5, 1 :11.75, 1 :12, 1:12.25, 1 :12.5, 1 :12.75, 1 :13, 1:13.25, 1 :13.5, 1 :13.75, 1:14, 1 :14.25, 1 :14.5, 1:14.75, 1 -15, 1 :15.25, 1 :15.5, 1 :15.75, 1 :16, 1 :16.25, 1:16.5, 1:16.75, 1:17, 1 :17.25, 1 :17.5, 1:17.75, 1 :18, 1 :18.25, 1:18.5, 1 :18.75, 1 :19, 1:19.25, 1:19.5, and 1:1
  • Disintegration agents assist in rapid disintegration of solid formulations by absorbing water and expanding.
  • Exemplary disintegration agents include polyvinylpyrrolidone (PVP, e.g. sold under the name POVIDONE), a cross- linked form of povidone (CPVP, e.g. sold under the name CROSPOVIDONE), a cross-linked form of sodium carboxymethylcellulose (NaCMC, e.g. sold under the name AC-DI-SOL), other modified celluloses, and modified starch.
  • PVP polyvinylpyrrolidone
  • CPVP cross- linked form of povidone
  • NaCMC sodium carboxymethylcellulose
  • Tablets formulated with CPVP exhibited much more rapid disintegration than tablets formulated with PVP.
  • Exemplary concentrations of the disintegration agent in a stable table formulation of the present invention are between about 1 wt% to about 20 wt%.
  • concentrations are between about 3 wt% and about 10 wt%.
  • concentrations of disintegration of at least about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, and 3.0 wt%, or concentrations up to about 4.0, 4.1, 4.2, 4.3, 4.4, 4.5 5 4.6, 4.7, 4.8, 4.9, 5.0, 5.2, 5.4, 5.6, 5.7, 5.8, 6.0, 6.25, 6.5, 6.75, 8.0, 8.25, 8.5, 8.75, 9.0, 9.25, 9.5, 9.75, and 10.0 wt%.
  • the weight ratio of disintegration agent to tetrahydrobiopterin in a stable tablet formulation of the present invention is, for example, in the range of about 1 :5 to about 1 :10. Also contemplated are weight ratios of about 1 :5.25, 1 :5.5, 1:5.75, 1:6.0, 1:6.25, 1 :6.5, 1 :6.75, 1:7.0, 1 :7.25, 1:7.5, 1 :7.75, 1 :8.0, 1 :8.25, 1:8.5, 1:8.75, 1 :9.0, 1 :9.25, 1:9.5, and 1:9.75.
  • Antioxidants may be included and help stabilize the tetrahydrobiopterin product, especially after dissolution.
  • Low pH aqueous solutions of API are more stable than are solutions at high pH.
  • Exemplary acidic antioxidants include ascorbic acid, fatty acid esters of ascorbic acid such as ascorbyl palmitate and ascorbyl stearate, and salts of ascorbic acid such as sodium, calcium, or potassium ascorbate.
  • Non-acidic antioxidants may also be u:-w ⁇ in the stable tablet formulations. Nenlimiting examples of non-acidic antioxidants ⁇ eiu ⁇ e b ⁇ a-carcterie. alpha- tocopherol.
  • Acidic additives may be added to enhance stability of tlie tabiet formulation, including citric acid or malic acid.
  • Exemplary concentrations of the antioxidant in a stable table formulation of the present invention are between about 1 wt% and about 3 wt%. Particularly contemplated concentrations are at least about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, and 2.0 wt%, or concentrations up to about 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, and 3.0 wt%.
  • the weight ratio of antioxidant to tetrahydrobiopterin in a stable tablet formulation of the present invention is, for example, in the range of about 1 :5 to 1 :30.
  • weight ratios of about 1 :5.5, 1 :6, 1 :6.5, 1 :7, 1 :7.5, 1 :8, 1:8.5, 1:9, 1:9.5, 1:10, 1:10.5, 1 :11, 1:11.5, 1 :12, 1 :12.5, 1:13, 1 :13.5, 1:14, 1:14.5, 1 :15, 1 :15.5, 1:16, 1 :16.5, 1:17, 1:17.5, 1 :18, 1:18.5, 1:19, 1:19.5, 1:20, 1 :20.5, 1:21, 1 :21.5, 1:22, 1 :22.5, 1:23, 1 :23.5, 1 :24, 1:24.5, 1 :25, 1 :25.5, 1:26, 1 :26.5, 1:27, 1 :27.5, 1 :28, 1 :28.5, 1 :29, and 1 :29.5.
  • ascorbic acid is present at a ratio of 1 :1 to BH4.
  • concentration of ascorbic acid in the stable formulations of the invention is far lower, e.g. a weight ratio (mg/mg) of 1 :20 of ascorbic acid to BH4.
  • the invention also contemplates formulations comprising ascorbic acid at a ratio to BH4 of less than 1 :1, e.g.
  • Lubricants improve stability, hardness and uniformity of solid formulations.
  • Exemplary lubricants include stearyl fumarate and magnesium stearate.
  • concentrations of the lubricant in a stable tablet formulation of the present invention are between about 0.1 wt% and about 2 wt%. Particularly contemplated concentrations are between about 0.5 and 1 wt%. Also contemplated are concentrations of lubricant of at least about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, and 1.0 wt%, or concentrations up to about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, and 2.0 wt%.
  • the weight ratio of lubricant to tetrahydrobiopterin in a stable tablet formulation of the present invention is, for example, in the range of about 1 :25 to 1 65.
  • weight ratios of about 1 :26, 1:27, 1 :28, 1:29, 1 :30, 1 :31, 1 :32, 1:33, 1 :34, 1 :35, 1 :36, 1 :37, 1 :38, 1:39, 1 :40, 1 :4 ! , 1 :43, 1 :44. 1 :45, 1 :46, [A ⁇ ' ' ⁇ 1:48, 1 :49, 1:50, 1 :51, 1 :52, 1 :53, 1:54, 1 :55, ⁇ :5 ⁇ . 1 :57, 1 :5?:.
  • llie stable solid formulation may op ( iona3]> include othei therapeutic agents suitable for the condition to be treated, e.g. folates, including folate precursors, folic acids, or folate derivatives; and/or arginine; and/or vitamins, such as vitamin C and/or vitamin B2 (riboflavin) and/or vitamin B 12; and/or neurotransmitter precursors such as L-dopa or carbidopa; and/or 5-hydroxytryptophan.
  • folates including folate precursors, folic acids, or folate derivatives
  • arginine arginine
  • vitamins such as vitamin C and/or vitamin B2 (riboflavin) and/or vitamin B 12
  • neurotransmitter precursors such as L-dopa or carbidopa; and/or 5-hydroxytryptophan.
  • Exemplary folates including folate precursors, folic acids, or folate derivatives, are disclosed in U.S. Patent Nos. 6,011,040 and 6,544,994, both of which are incorporated herein by reference, and include folic acid (pteroylmonoglutamate), dihydrofolic acid, tetrahydrofolic acid, 5-methyltetrahydrofolic acid, 5,10- methylenetetrahydrofolic acid, 5,10-methenyltetrahydrofolic acid, 5,10- formiminotetrahydrofolic acid, 5-formyltetrahydrofolic acid (leucovorin), 10- formyltetrahydrofolic acid, 10-methyltetrahydrofolic acid, one or more of the folylpolyglutamates, compounds in which the pyrazine ring of the pterin moiety of folic acid or of the folylpolyglutamates is reduced to give dihydrofolates or tetrahydrof
  • Exemplary tetrahydrofolates include 5-formyl-(6S)-tetrahydrofolic acid, 5-methyl- (6S)-tetrahydrofolic acid, 5,10-methylene-(6R)-tetrahydrofolic acid, 5,10-methenyl- (6R)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid, 5-formimino-(6S)- tetrahydrofolic acid or (6S)-tetrahydrofolic acid, and pharmaceutically acceptable salts thereof.
  • Exemplary salts include sodium, potassium, calcium or ammonium salts.
  • Exemplary relative weight ratios of BH4 to folates to arginine may be from about 1:10:10 to about 10:1 :1.
  • the stable formulations of the invention can also comprise other excipients such as mannitol, hydroxyl propyl cellulose, microcrystalline cellulose, or other non-reducing sugars such as sucrose, trehalose, melezitose, planteose, and raffinose. Reducing sugars may react with BH4.
  • compositions for oral administration may be incorporated, for example, b> ad' i living the components and optionally finely dividing them, and then tilling capsule ⁇ , composed for example from hard or soft gelatin, compressing tablets, pills or troches. Coatings may be applied after compression to form pills.
  • Pharmaceutically acceptable ingredients are well known for the various types of formulation and may be for example binders such as natural or synthetic polymers, excipients, lubricants, surfactants, sweetening and flavouring agents, coating materials, preservatives, dyes, thickeners, adjuvants, antimicrobial agents, antioxidants and carriers for the various formulation types.
  • binders such as natural or synthetic polymers, excipients, lubricants, surfactants, sweetening and flavouring agents, coating materials, preservatives, dyes, thickeners, adjuvants, antimicrobial agents, antioxidants and carriers for the various formulation types.
  • Nonlimiting examples of binders useful in a composition described herein include gum tragacanth, acacia, starch, gelatine, and biological degradable polymers such as homo- or co-polyesters of dicarboxylic acids, alkylene glycols, polyalkylene glycols and/or aliphatic hydroxyl carboxylic acids; homo- or co-polyamides of dicarboxylic acids, alkylene diamines, and/or aliphatic amino carboxylic acids; corresponding polyester-polyamide-co- polymers, polyanhydrides, polyorthoesters, polyphosphazene and polycarbonates.
  • the biological degradable polymers may be linear, branched or crosslinked.
  • polymers are poly-glycolic acid, poly-lactic acid, and poly-d,l-lactide/glycolide.
  • Other examples for polymers are water-soluble polymers such as polyoxaalkylenes (polyoxaethylene, polyoxapropylene and mixed polymers thereof, poly-acrylamides and hydroxylalkylated polyacrylamides, poly-maleic acid and esters or -amides thereof, poly-acrylic acid and esters or -amides thereof, poly-vinylalcohol und esters or -ethers thereof, poly-vinylimidazole, poly- vinyl pyrrolidon, und natural polymers like chitosan.
  • Nonlimiting examples of excipients useful in a composition described herein include phosphates such as dicalcium phosphate.
  • Nonlimiting examples of lubricants use in a composition described herein include natural or synthetic oils, fats, waxes, or fatty acid salts such as magnesium stearate.
  • Surfactants for use in a composition described herein can be anionic, anionic, amphoteric or neutral.
  • Nonlimiting examples of surfactants useful in a composition described herein include lecithin, phospholipids, octyl sulfate, decyl sulfate, dodecyl sulfate, tetradecy !
  • l-decanoylaminoethane-2-sulfonic acid 1- dodecanoylaminoethane-2-sulfonic acid, 1 -tetradecanoylaminoethane-2-sulfonic acid, l-hexadecanoylaminoethane-2-sulfonic acid, and l-octadecanoylaminoethane-2- sulfonic acid, and taurocholic acid and taurodeoxycholic acid, bile acids and their salts, such as cholic acid, deoxycholic acid and sodium glycocholates, sodium caprate or sodium laurate, sodium oleate, sodium lauryl sulphate, sodium cetyl sulphate, sulfated castor oil and sodium dioctylsulfosuccinate, cocamidopropylbetaine and laurylbetaine, fatty alcohols, cholesterols, glycerol mono- or -distearate, gly
  • Nonlimiting examples of sweetening agents useful in a composition described herein include sucrose, fructose, lactose or aspartame.
  • Nonlimiting examples of flavoring agents for use in a composition described herein include peppermint, oil of wintergreen or fruit flavors such as cherry or orange flavor.
  • Nonlimiting examples of coating materials for use in a composition described herein include gelatin, wax, shellac, sugar or other biological degradable polymers.
  • Nonlimiting examples of preservatives for use in a composition described herein include methyl or propylparabens, sorbic acid, chlorobutanol, phenol and thimerosal.
  • the polymorph described herein may also be formulated as effervescent tablet or powder, which disintegrate in an aqueous environment to provide a drinking solution.
  • Slow release formulations may also be prepared from the polymorph described herein in order to achieve a controlled release of the active agent in contact with the body fluids in the gastro iniestinal tract, and to provide a substantial constant and effective level of the active agent in the blood plasma.
  • the crystal form may be embedded for this purpose in a polymer matrix of a biological degradable polymer, a water-soluble polymer or a mixture of both, and optionally suitable surfactants. Embedding can mean in this context the incorporation of micro- particles in a matrix of polymers.
  • Controlled release formulations are also obtained through encapsulation of dispersed micro-particles or emulsified micro-droplets via known dispersion or emulsion coating technologies.
  • the BH4 used m a composition described herein is preferably formulated as a dihydrochloiiie salt, liov.cev. ⁇ is contemplated that other salt forms of BHA possess the desired biological activity, and consequently, ether salt forms of BH4 can be used.
  • BI/4 sails wi!h inorganic or organic acids are preferred.
  • Nonlimiting examples of alternative BW salts forms includes BH4 salts of acetic acid, citric acid, oxalic acid, tartaric acid, fumaric acid, and mandelic acid.
  • Pharmaceutically acceptable base addition salts may be formed with metals or amines, such as alkali and alkaline earth metals or organic amines.
  • Pharmaceutically acceptable salts of compounds may also be prepared with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are also possible. Examples of metals used as cations are sodium, potassium, magnesium, ammonium, calcium, or ferric, and the like.
  • Suitable amines include isopropylamine, trimethylamine, histidine, N.N' dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N methylglucamine, and procaine.
  • Pharmaceutically acceptable acid addition salts include inorganic or organic acid salts. Examples of suitable acid salts include the hydrochlorides, acetates, citrates, salicylates, nitrates, phosphates.
  • Suitable pharmaceutically acceptable salts include, for example, acetic, citric, oxalic, tartaric, or mandelic acids, hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fuma ⁇ c acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4 aminosalicylic acid, 2 phenoxybenzoic acid, 2 acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with
  • glucose ⁇ ⁇ b ⁇ >pha ⁇ e N eycloh ⁇ xylsulfdniic acid (with * the formation of L-ychimates), or with othei acid organic compounds, such as ascorbic acid.
  • the stable formulations of the invention may be provided, e.g. as tablets or pills or capsules in HDPE bottles provided with a dessicant capsule or pouch; or in foil-on-foil blister packaging, or in blister packaging comprising see- through polymer film, if commercially desirable.
  • phrases "pharmaceutically or pharmacologically acceptable” refers to molecular entities and compositions that do not produce adverse, allergic, or other untoward reactions when administered to an animal or a human.
  • pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the therapeutic compositions, its use in therapeutic compositions is contemplated. Supplementary active ingredients also can be incorporated into the compositions.
  • pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
  • the use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients also can be incorporated into the compositions.
  • the pharmaceutical compositions and treatment methods of the invention may be useful in fields of human medicine and veterinary medicine.
  • the subject to be treated may be a mammal, preferably human or other animal.
  • subjects include for example, farm animals including cows, sheep, pigs, horses and goats, companion animals su ;h as dogs and cii-s, exotic and/or zoo animals, laboratory animals including mice rats " , rabbits. ⁇ ni;?e.: pigs ai;d hamsters; and poultry such as chickens, turkey ducks and geese.
  • the stable fo ⁇ nulations of the invention may be used for treatment of conditions associated with elevated phenylalanine levels or decreased tyrosine or tryptophan levels, which may be caused, for example, by reduced phenylalanine hydroxylase, tyrosine hydroxylase, or tryptophan hydroxylase activity.
  • Conditions associated v. ⁇ th elevated phenylalanine levels specifically include phenylketonuria, both mild and classic, and hyperphenylalaninemia as described herein, and exemplary patient populations include the patient subgroups described herein as well as any other patient exhibiting phenylalanine levels above normal.
  • Conditions associated with decreased tyrosine or tryptophan levels include neurotransmitter deficiency, neurological and psychiatric disorders such as Parkinson's, dystonia, spinocerebellar degeneration, pain, fatigue, depression, other affective disorders and schizophrenia.
  • the stable formulations may also be used for treating patients suffering from BH4 deficiency, e.g., due to a defect in the pathway for its synthesis, including but not limited to dopa-responsive dystonia (DRD), sepiapterin reductase (SR) deficiency, or dihydropteridine reductase (DHPR) deficiency.
  • DDD dopa-responsive dystonia
  • SR sepiapterin reductase
  • DHPR dihydropteridine reductase
  • Suitable subjects for treatment with the stable formulations of the invention include subjects with an elevated plasma Phe concentration in the absence of the therapeutic, e.g. greater than 1800 ⁇ M/L, or greater than 1600 ⁇ M, greater than 1400 ⁇ M, greater than 1200 ⁇ M, greater than 1000 ⁇ M, greater than 800 ⁇ M, or greater than 600 ⁇ M, greater than 420 ⁇ M, greater than 300 ⁇ M, greater than 200 ⁇ M, or greater than 180 ⁇ M.
  • Mild PKU is generally classified as plasma Phe concentrations of up to 600 ⁇ M/L, moderate PKU as plasma Phe concentrations of between 600 ⁇ M/L to about 1200 ⁇ M/L and classic or severe PKU as plasma Phe concentrations that are greater than 1200 ⁇ M/L.
  • Preferably treatment with the stable formulations alone or with protein-restricted diet decreases the plasma phenylalanine concentration of the subject to less than 600 ⁇ M, or less than 500 ⁇ M, ⁇ r 360 ⁇ M ⁇ 15 ⁇ M or less, or less than 200 ⁇ M, or less than 100 ⁇ M.
  • Other suitable subjects include subjects diagnoses ⁇ s having a reduced phenylalanine hydroxylase (P -S. H; activity. Redu'.-e.J PAH activity rray result from a mutation in the P ⁇ H cnz> ⁇ -e.
  • Exemplary patient populations and exemplary 8H4 loading tests are described in Int'l. Publication No. WO 2005/049000, incorporated herein by reference in its entirety.
  • Typical dosages of the BH4 comprise about 1 to about 20 mg/kg body weight per day, which will usually amount to about 5 (1 mg/kg x 5kg body weight) to 3000 mg/day (30mg/kg x 100kg body weight). While continuous, daily administration is contemplated, for HPA it may be desirable to cease the BH4 therapy when the symptoms of Phe levels are reduced to below a certain threshold level. Of course, the therapy may be reinitiated in the event that Phe levels rise again. Appropriate dosages may be ascertained through the use of established assays for determining blood levels of Phe in conjunction with relevant dose response data.
  • the methods of the present invention will provide to a patient in need thereof, a daily dose of between about 10 mg/kg to about 20 mg/kg of BH4.
  • a daily dose of between about 10 mg/kg to about 20 mg/kg of BH4.
  • the daily dose may be administered ⁇ n ⁇ x single Jose, or alternatively. may be administered in multiple doses at conveniently spaced intervals.
  • the daily dose may be 1 mg/kg, 2 mg/kg, 3 mg/kg, 4 tog/kg, 5 mg/kg, 6 mg/kg, 7 mg/kg, 8 mg/kg, 9 mg/kg, 10 mg/kg, 11 -mg/kg, 12 mg/kg, 13 mg/kg, 14 mg/kg, 15 mg/kg, 16 mg/kg, 17 mg/kg, 18 mg/kg, 19 mg/kg, 20 mg/kg, 22 mg/kg, 24 mg/kg, 26 mg/kg, 28 mg/kg, 30 mg/kg, 32 mg/kg, 34 mg/kg, 36 mg/kg, 38 mg/kg, 40 mg/kg, 42 mg/kg, 44 mg/kg, 46 mg/kg, 48 mg/kg, 50 mg/kg, or more mg/kg.
  • the invention further contemplates that stable formulations of the invention may be used for treatment of subjects suffering from conditions that would benefit from enhancement of nitric oxide synthase activity and patients suffering from vascular diseases, ischemic or inflammatory diseases, or insulin resistance.
  • the treatment may, for example alleviate a deficiency in nitric oxide synthase activity or may, for example provide an increase in nitric oxide synthase activity over normal levels. It has been suggested that a patient suffering from a deficiency in nitric oxide synthase activity would benefit from co-treatment with folates, including folate precursors, folic acids, or folate derivatives.
  • Nitric oxide is constitutively produced by vascular endothelial cells where it plays a key physiological role in the regulation of blood pressure and vascular tone. It has been suggested that a deficiency in nitric oxide bioactivity is involved in the pathogenesis of vascular dysfunctions, including coronary artery disease, atherosclerosis of any arteries, including coronary, carotid, cerebral, or peripheral vascular arteries, ischemia-reperfusion injury, hypertension, diabetes, diabetic vasculopathy, cardiovascular disease, peripheral vascular disease, or neurodegenerative conditions stemming from ischemia and/or inflammation, such as stroke, and that such pathogenesis includes damaged endothelium, insufficient oxygen flow to organs and tissues, elevated systemic vascular resistance (high blood pressure), vascular smooth muscle proliferation, progression of vascular stenosis (narrowing) and inflammation. Thus, treatment of any of these conditions is contemplated according to methods of the invention.
  • Diseases having vascular dysfunction associated with insulin resistance include those caused by insulin resistance or aggravated by insulin resistance, or those for which cure is retarded by insulin resistance, such as hypertension, hyperlipidemia, arteriosclerosis, coronary vasoconstrictive angina, effort angina, cerebrovascular constrictive lesion, cerebrovascular insufficiency, cerebral vasospasm, peripheral circulation disorder, coronary arteriorestenosis following percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass grafting (CABG), obesity, insulin-independent diabetes, hyperinsulinemia, lipid metabolism abnormality, coronary arteriosclerotic heart diseases or the like so far as they are associated with insulin resistance.
  • PTCA percutaneous transluminal coronary angioplasty
  • CABG coronary artery bypass grafting
  • BH4 when administered to patients with these diseases, can prevent or treat these diseases by activating the functions of NOS, increasing NO production and suppressing the production of active oxygen species to improve disorders of vascular endothelial cells.
  • suitable dose of a composition according to the present invention will depend upon the age, health and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired (i.e., the amount of decrease in plasma Phe concentration desired). The frequency of dosing also is dependent on pharmacodynamic effects on Phe levels. If the effect lasts for 24 hours from a single dose.
  • the most preferred dosage can be tailored to the individual subject, as is understood and determinablc by one of skill in the art, without undue experimentation. This typically involves adjustment of a standard dose, e.g., reduction of the dose if the patient has a low body weight.
  • the frequency of BH4 dosing will depend on the pharmacokinetic parameters of the agent and the routes of administration.
  • the optimal pharmaceutical formulation will be determined by one of skill in the art depending on the route of administration and the desired dosage. See for example Remington's Pharmaceutical Sciences. 18th Ed. (1990, Mack Publ. Co, Easton P ⁇ 18042) pp 1435 1712, incorporated herein by reference. Such formulation!
  • ⁇ * may i nfluence the physical state, ctahi ⁇ ty, rate of in vivo release and rate of in ⁇ ivo ci idiitncv of die administered - rigenK-.
  • dose 1 may be calculated according to body weight, body surface areas oi org-'n size. Further refinement of the calculations necessary to determine the appropriate treatment dose is routinely made by those of ordinary skill in the art without undue experimentation, especially in light of the dosage information and assays disclosed herein as well as the pharmacokinetic data observed in animals or human clinical trials.
  • the final dosage regimen will be determined by the attending physician, considering factors which modify the action of drugs, e.g., the drug's specific activity, severity of the damage and the responsiveness of the patient, the age, condition, body weight, sex and diet of the patient, the severity of any infection, time of administration and other clinical factors. As studies are conducted, further information will emerge regarding appropriate dosage levels and duration of treatment for specific diseases and conditions.
  • administration of the stable formulations of the invention may be concurrent with or may precede or follow the administration of the second therapeutic agent, e.g. by intervals ranging from minutes to hours, so long as both agents are able to exert their therapeutic effect at overlapping time periods.
  • the invention contemplates the stable formulations of the invention for use with a second therapeutic agent.
  • the invention also contemplates use of a second therapeutic agent in preparation of a medicament for administration with the stable tetrahydrobiopterin, precursor, derivative or analog formulations of the invention.
  • Tetrahydrobiopterin therapy may be combined with dietary protein restriction to effect a therapeutic outcome in patients with various forms of HPA.
  • This process may involve administering the BH4 composition and the dietary protein therapeutic composition at the same lime. This may be achieved by administering a single composition or pharmacological protein formulation that includes all of the dietary protein requirements and also includes the BH4 within said protein formulation.
  • the dietary protein (supplement or normal protein meal) is taken at about the same time as a pharmacological formulation (tablet, injection or drink) of BH4.
  • the BH4 treatment may precede or follow the dietary protein therapy by intervals ranging from minutes to hours.
  • the protein and the BH4 compositions are administered separately, one would generally ensure that a significant period of time did not expire between the time of each delivery, such that the BH4 will still be able to exert an advantageously effect on the patient.
  • the BH4 therapy will be a continuous therapy where a daily dose of BH4 is administered to the patient indefinitely.
  • a daily dose of BH4 is administered to the patient indefinitely.
  • the methods of the present invention also contemplate combination therapy with a third composition that specifically targets one or more of the symptoms of HPA. For example, it is known that the deficit in tyrosine caused by HPA results in a deficiency in neurotransmitters dopamine and serotonin.
  • BH4 and dietary protein based methods could be further combined with administration of L-dopa, carbidopa and 5-hydroxytryptophan neurotransmitters to correct the defects that result from decreased amounts of tyrosine in the diet.
  • tyrosine is an essential amino acid for such patients. Therefore dietary supplementation with tyrosine may be desirable for patients receiving phenylase in combination with the BH4 therapy.
  • Formulation I Formulation Il Formulation III
  • Ingredient wt %) (wt %) (wt %) R-L-erythro-5, 6, 7, 8-tetrahydrobiopterin dihydrochloride salt, polymorph B 33.33 33.33 33.33
  • the tablet samples 150 mg, 300 mg, and 600 mg
  • a tablet press available from Jenn- Chiang Mahinery Co., Ltd., Taiwan, R.O.C.
  • the parameters of the tablet press were set to provide tablets with a thickness in the range of 4.5 to 5.5 millimeters, and a target hardness of 7 KP.
  • the resulting tablets were then analyzed to determine the stability of the formulations.
  • the stability of the formulations was studied for a change in
  • Color is surface, and surface, and surface
  • Appearance off white color is light color is light and color is yellow yellow yellow
  • tablet Formulation HI is more stable t&t the other formulations of BH4.
  • Each of the pharmaceutical preparations are useful fermn ' aijons for the delivery of BH4.
  • Formulation III exhibilod better sfaoility tlihi Formulations I and II.
  • ti>. stabilized., tablet. fo ⁇ rnuat'on comprises an optimal disintegration agent, for example, crossprovid ⁇ ne or -a disintegration agent more similar to polyvinylpyrrolidone than hydroxypropylcellulose.
  • the preferred formulation is Formulation III.
  • Other suitable tablet formulations may include at least ascorbic acid at a concentration of at least 0.01 % weight, or at least 0.05% weight or at least 0.1 % weight.
  • Three hundred mg tablets containing 100 mg tetrahydrobiopterin are prepared using the desired initial amount of polymorph B and mixing with other ingredients in the relative amounts shown below in Table III using the following dry tableting process. Tablets containing other desired amounts of tetrhydrobiopterin can be prepared in a similar manner.
  • the 6R-L-erythro-5, 6, 7, 8-tetrahydrobiopterin and D-Mannitol were hand screened with a 20 mesh screen (designed to filter out particles greater than ⁇ 850 ⁇ m in size) and placed in a blender. The mixture was blended for 10 minutes at 21 RPM.
  • the Anhydrous Dibasic Calcium Phosphate and CROSPO VIDONE were hand screened with a 20 mesh screen and blended with the BH4 and D-Mannitol for 10 minutes at 21 RPM.
  • the Ascorbic Acid and Riboflavin were added to the blender after hand screening with a 20 mesh screen, and the resulting mixture blended for 10 minutes at 21 RPM.
  • the Sodium Stearyl Fumarate was added to the blender after hand screening with a 40 mesh screen, and blended for 5 minutes at 21 RPM. The blended mixture was then discharged into a bag and tested for uniformity, before being pressed into tablets.
  • the tablets were packaged either in foil blister-packs, or in HDPE bottles in quantities of 45-tablets per bottle. Each type of packaged tablets were divided into two batches. One batch was stored at room temperature, 25+2 0 C, and 60+5% relative humidity. The other batch was stored under accelerated testing conditions, at 40+2 0 C and 75+5% relative humidity. At regular intervals, tablets were removed from storage and tested for retention of the active pharmaceutical ingredient, 6R-L-erythro-5, 6, 7, 8-tetrahydrobiopterin. Exemplary results for the 300 mg tablets are shown below in Tables IV, V, VI and VII.
  • each of the four batches showed retention of at least 99% of the original amount of 6R-L-er ⁇ thro-5, 6, 7, 8- tetrahydrobiopterin by HPLC assay, loss on drying of less than 1%, and rapid disintegration in 3 minutes or less.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention is directed to a stable solid formulations of tetrahydrobiopterin, processes for producing them, and treatment methods using such formulations.

Description

STABLE TABLET FORMULATION BACKGROUND
Field
The present invention is generally directed to stable tablet formulations of tetrahydrobiopterin or precursors, derivatives or analogs thereof for the treatment of humans.
Background of the Related Technology
Tetrahydrobiopterin (sometimes referred to as BH4) is a biogenic amine of the naturally-occurring pterin family that is a cofactor for a number of different enzymes, including phenylalanine hydroxylase (PAH), tyrosine hydroxylase, tryptophan hydroxylase and nitric oxide synthase. Pterins are present in physiological fluids and tissues in reduced and oxidized forms, however, only the 5,6,7,8, tetrahydrobiopterin is biologically active. It is a chiral molecule and the 6R enantiomer of the cofactor is known to be the biologically active enantiomer. For a detailed review of the synthesis and disorders of BH4 see Blau et al., 2001 (Disorders of tetrahydrobiopterin and related biogenic amines. In: Scriver CR, Beaudet AL, Sly WS, Vallc D, Chi '.^5 3. VogelsteJn B, eds. The Metabolic and Molecular Bases of Inherited Dissat-e. Sth ed. Mew Yoik: McGraw-Hill, 2001 : 1275-1776).
A deficiency in PAH activity, due to absent or mutated PAH enzyme or a deficiency in its cofactor BH4, manifests as an excess of the amino acid phenylalanine (Phe) known as hyperphenylalaninemia (HPA) in its very mildest forms or phenylketonuria (PKU) in its moderate or severe forms. PAH deficiency also causes a deficiency in the amino acid tyrosine, which is a precursor for synthesis of neurotransmitters. A deficiency in tyrosine hydroxylase or tryptophan hydroxylase activity can manifest as a deficiency in neurotransmitter production.
Despite the elucidation of the role of BH4 deficiency in phenylketonuria, treatment with BH4 has not been suggested because such treatment is very expensive, as high as $30,000 per year for an adolescent or adult, as compared with $6,000 for phenylalanine-restπcted dietary therapy (Hanley, N. Engl. J. Med 348(17): 1723, 2003). Another significant problem with BH4 is that this compound is unstable and readily undergoes aerobic oxidation at room temperature (Davis et al., Eur. J. Biochem., VoI 173, 345-351, 1988; U.S. Patent No. 4,701,455) and has a shelf-life of less 8 hours at room temperature (Berneggar and Blau, MoI. Genet. Metabol. 77:304-313, 2002).
Other tetrahydrobiopterin products available on the market need to be specially packaged or kept frozen. For example the labeling on the tablets sold by Schirck's Laboratory specify that the tablets should be kept frozen and state that the product has a shelf life at room temperature of only 2 months. BIOPTEN (tetrahydrobiopterin granules) requires expensive, hermetically-sealed foil packaging to maintain room temperature stability. The instability of such BH4 compositions is commercially undesirable and significant degradation due to improper storage could hinder therapy of patients.
Drug substance polymorphic forms can exhibit different physical and mechanical properties, including hygroscopicity, particle shape, density, flowability, and compactibility, which in turn may affect processing of the drug substance and/or manufacturing of the drug product. The effect of polymorphism on pharmaceutical processing also depends on the formulation and the manufacturing process. Polymorphic forms of the drug substance can undergo phase conversion when exposed tυ a range of manufacturing processes, such as drying, milling, micronization, wet granulation, spray-drying, and compaction. Exposure to environmental conditions such as humidity and temperature can also induce polymorph conversion. The extent of conversion generally depends on the relative stability of the polymorphs, kinetic barriers for phase conversion, and applied stress. See FDA Center for Drug Evaluation and Research (CDER) Draft Guidance for Industry ANDAs: Pharmaceutical Solid Polymorphism Chemistry, Manufacturing, and Controls Information, December 2004. Thus, there remains a need for a stable solid formulation of tetrahydrobiopterin and processes for manufacturing such stable formulations. The present invention is directed to addressing such a need. SUMMARY OF THE INVENTION
The present invention relates to stable solid formulations of tetrahydrobiopterin, particularly stable tablets, processes for producing such formulations, and treatment methods using such formulations.
The invention provides a stable solid formulation of tetrahydrobiopterin, or a precursor or derivative or analog thereof, that maintains its stability for an extended period of time. Compositions of the invention may comprise a stable, crystalline form of BH4 that is stable at room temperature for more than 8 hours and a pharmaceutically acceptable carrier, diluent or excipient. Exemplary stable tablets of the invention have been prepared using a dry tableting process and have been shown to have a shelf-life of at least 6 to 9 months at room temperature.
Another aspect of the invention provides a dry formulation process for preparing stable solid formulations, which includes the step of mixing tetrahydrobiopterin, or a precursor or derivative or analog thereof, with another pharmaceutical carrier, diluent or excipient, in the absence of added water.
In an exemplary embodiment, the active pharmaceutical ingredient and excipients are dry blended and compressed. The tablets are processed in humidity- controlled rooms where humidity is kept at about 65% (+ 5%) or less. Once processed, the tablets are stored in triple plastic lined water resistant containers with desiccant pillows lined between the outer two layers of plastic bags. Thus, the invention includes a dry formulation method comprising the steps of mixing an initial amount of a crystalline polymorph of (6R)-L-erythro-tetrahydrobiopterin, preferably polymorph B, and one or more pharmaceutically acceptable excipients, and forming a tablet from the mixture, wherein the steps do not include adding liquid water. Exemplary particle sizes include, e.g., from about 0.2 μm to about 500 μm, from about 1 μm to about 250 μm, or from about 2 μm to about 200μm, or, e.g., larger than about 500 μm, larger than about 600 μm, larger than about 700 μm, or smaller than about 850 μm. In exemplary embodiments, the tablet is initially manufactured using a stable crystalline form of (6R)-5,6,7,8-tetrahydrobiopterin described below as "polymorph B," and retains at least about 95% of the active pharmaceutical ingredient (API) at room temperature after 3 months, 6 months or 9 months, or preferably 12 months or longer, e.g. 15 months, 18 months, 21 months, 2 years, 2.5 years, 3 years or longer. Preferably the tablet retains at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.5% of the API after storage at room temperature for such time periods. The tablet also preferably exhibits loss on drying of 2% or less, or 1.5% or less, or 1% or less, or 0.9% or less, or 0.8% or less, or 0.7% or less, or 0.6% or less, after such time periods. Exemplary tablets may be manufactured wherein the initial amount of tetrahydrobiopterin active pharmaceutical ingredient is about 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg or higher doses. Preferred tablets also exhibit rapid disintegration upon administration, e.g., 3 minutes or less, to improve ease of administration.
Thus, the invention provides a stable tablet formulation comprising an initial amount of a crystalline polymorph, designated polymorph B, of (6R)-L- erythro-tetrahydrobiopterin and a pharmaceutically acceptable excipient, wherein after six months at room temperature and about 60% humidity the stable tablet formulation retains at least about 95% of the initial amount of (όR)-L-erythro- tetrahydrobiopterin, and wherein said crystalline polymorph, as a hydrochloride salt, exhibits an X-ray powder diffraction pattern with the following characteristic peaks expressed in d-values(A) : 8.7 (vs), 5.63 (m), 4.76(m), 4.40 (m), 4.00 (s), 3.23 (s), 3.11 (vs), preferably 8.7 (vs), 6.9 (w), 5.90 (vw), 5.63 (m), 5.07 (m), 4.76 (m), 4.40 (m), 4.15 (w), 4.00 (s), 3.95 (m), 3.52 (m), 3.44 (w), 3.32 (m), 3.23 (s), 3.17 (w), 3.11 (vs), 3.06 (w), 2.99 (w), 2.96 (w), 2.94 (m), 2.87 (w), 2.84 (s), 2.82 (m), 2.69 (w), 2.59 (w), and 2.44 (w). Preferably the tablet retains at least about 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.5% of the initial amount of (6R)-L- erythro-tetrahydrobiopterin.
The stable solid formulation preferably contains one or more of the following additional ingredients that improve stability or other characteristics of the formulation: binder, disintegrant, acidic antioxidant, or lubricant or combinations thereof. One exemplary preferred composition includes anhydrous dibasic calcium phosphate, crospovidone, ascorbic acid and stearyl fumarate, optionally with mannitol and riboflavin. The stable solid formulation may optionally include other therapeutic agents suitable for the condition to be treated, e.g. folates, including folate precursors, folic acids, or folate derivatives; and/or vitamins such as vitamin C and/or vitamin B 12; and/or neurotransmitter precursors such as L-dopa or carbidopa; and/or 5- hydroxytryptophan; and/or arginine. Compositions comprising tetrahydrobiopterin (or a precursor or derivative or analog) and a folate, and optionally further comprising arginine, are particularly contemplated.
The invention further contemplates other stable solid formulations for oral administration, e.g. capsules, pills or troches, with similar stability properties. Yet another aspect of the invention provides treatment methods using such stable solid formulations. The invention contemplates that such formulations of the invention are useful for intervention in metabolic disorders, particularly those involving amino acid metabolism. More particularly, the stable formulations may be used for the treatment of subjects exhibiting elevated phenylalanine levels or decreased tyrosine levels, for example, subjects suffering from hyperphenylalanemia, mild phenylketonuria or classic severe phenylketonuria: and tor the treatment of subjects suffering from conditions that would benefit frovi enhancement of nitric oxide synthase activity, including vascular diseases, ischemic or inflammatory diseases, diabetes, or insulin resistance. The total dose required for each treatment may be administered in multiple doses or in a single dose. The stable formulations may be administered daily or at some other interval, e.g., every alternative day or even weekly.
The stable formulations may be used alone or in conjunction with other therapies suitable for the disorder to be treated, including the underlying disease or the clinical symptoms. For example, for HPA, the stable formulations of the invention may be administered in combination with a protein-restricted diet, e.g. where the subject is limited to about 600 mg or less, or about 300 mg or less of protein daily, optionally with supplemental amino acids, such as tyrosine, valine, isoleucine and leucine. The stable formulations may also be administered in combination with folates, arginine, vitamins, or neurotransmitter precursors. As another example, for vascular diseases, diabetes, or insulin resistance, the stable formulations of the invention may be administered in conjunction with other therapeutic agents such as anti-hypertensive agents, anti-platelet agents, cholesterol-lowering agents, insulin or oral hypoglycemic agents.
Other features and advantages of the invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, because various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows a characteristic X-ray powder diffraction pattern for crystalline polymorph B of (6R)-5,6,7,8-tetrahydrobiopterin dihydrochloride.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The present invention provides a stable formulation that maintains a stable crystalline polymorph of the active ingredient. An anhydrous polymorph of (όR.)-5,6, 7,8-tetrahydrobiopterin dihydrochloride that is stable at room temperature to atmospheric oxygen and normal humidity, described below as polymorph B1 has been identified. However, when the percent relative humidity approaches 80%, polymorph B appears to take up much more water, loses its crystalline form, and becomes labile to oxidation.
By using a dry formulation process, the stable crystalline structure of this polymorph is maintained in the finished product. In contrast, other processes for preparing tetrahydrobiopterin compositions result in a less stable product compared to those of the present invention. Stable tablet formulations of the invention have been made using polymorph B in a dry formulation process and have been shown to retain 99% or more of the initial (6R)-5,6,7,8-tetrahydrobiopterin for at least 6 or 9 months, both at normal room temperature and humidity, and under accelerated testing conditions. The observed stability under accelerated testing conditions, i.e. higher temperature and humidity, indicates that the tablet formulations would be stable for far longer than 6 or 9 months at normal room temperature and humidity.
As used herein, "shelf life" means the storage period during which an active pharmaceutical ingredient (API) in a pharmaceutical formulation has minimal degradation (e.g., not more than about 5% degradation) when the pharmaceutical formulation is stored under specified storage conditions, for example, room temperature at normal humidity.
The shelf-life of the stable formulations of the invention may be measured as follows. The formulation to be tested may be divided into one or more different batches and stored under typical storage conditions, for example, 4 0C (refrigerator), or 25 0C (room temperature). Degradation of the API in a pharmaceutical formulation can also be detected using accelerated testing under exaggerated storage conditions designed to increase the degradation rate of the drug substance. For example, a batch can be "stressed" (placed in chamber which maintains a temperature of 45 0C and 75% humidity). Samples of each batch of formulation are then analyzed at different time points (e.g., time zero,.2 weeks, 1 month, 3 months, 6 months, 9 months, 1 year, 1.5 years, 2-years, 2.5 years, 3 years or longer) for amount of API still present in the formulation. Analysis of the API in the formulation may be carried out by a variety of detection methods including high performance liquid chromatography, crystal or powder X-ray diffraction, infrared or Raman spectra studies, microscopy, differential scanning calorimetry, thermal gravimetric analysis, hot-stage microscopy, and solid state nuclear magnetic resonance. Maintenance of a particular polymorph form can be determined by carrying out, e.g., powder or crystal X-ray diffraction studies or any of the same techniques used to analyze the polymorph initially.
I. Synthesis of tetrahydrobiopterin, precursors, derivatives and analogs
A variety of methods are known in the art for synthesis of tetrahydrobiopterins, precursors, derivatives and analogs. U.S. Patent Nos. 5,698,408; 2,601,215; 3505329; 4,540,783; 4,550,109; 4,587,340; 4,595,752; 4,649,197; 4,665,182; 4,701,455; 4,713,454; 4,937,342; 5,037,981; 5,198,547; 5,350,851; 5,401,844; 5,698,408, Canadian application CA 2420374, European application nos. EP 079 574, EP 191 335 and Suntory Japanese patent publications JP 4-082888, JP 59-021685 and JP 9-157270, as well as Sugimoto and Matsuura, Bull. Chem. Soc. Japan, 48(12):3767-3768 (1975), Sugimoto and Matsuura, Bull. Chem. Soc. Japan, 52(1):181-183 (1979), Matsuura et al., Chem. Lett. (Japan), 735-738 (1984),
Matsuura et al., Heterocycles, Vol. 23, No. 12, 3115-3120, 1985 and Whiteley et al., Anal Biochem. \37(2):394-6 (1984) (each incorporated herein by reference) each describe methods of making dihydrobiopterins, BH4 and derivatives thereof that may be used as compositions for the present invention. Int'l Publication No. WO2005049614, U.S. Patent No. 4,540,783,
Japanese Patent No. 59-021685, Schircks et al., HeIv. Chim. Acta, 60: 211 (1977), Sugimoto et al., Bull. Chem. Soc. Jp, 52(1):181 (1979), Sugimoto et al., Bull. Chem. Soc. Jp, 48(12):3767 (1975), Visontini et al., HeIv. Chim. Acta, 52:1225 (1969), and Matsuura et al., Chem. Lett., p 735 (1984), incorporated herein by reference in their entireties, describe methods of synthesizing BH4.
Nonlimiting examples of analogs for use in the compositions and methods described herein include pyridine, pterin, neopterin, biopterin, 7,8- Dihydrobiopterin, 6-methyltetrahydroρterin, and other 6-substituted tetrahydropterin and other 6-substituted tetrahydropterins, sepiapterin, 6,7-Dimethyltetrahydropterin, 6-methyl biopterin and other 6-substituted biopterins, and other analogs that are described in the art. Nonlimiting examples of derivatives for use in the compositions and methods described herein include the derivatives described in U.S. Patent Nos. 4,758,571; 4,774,244; 6,162,806; 5,902, 810; 2,955,110; 2,541,717; 2,603,643; and 4,371,514, the disclosures of which are hereby incorporated herein. Any such methods or other methods known in the art may be used to produce BH4, or precursors, derivatives or analogs for use in the stable formulations and therapeutic methods of the present invention. II. Crystal Polymorphs of 6R-tetrahydrobiopterin hydrochloride salt
It has been found that BH4, and in particular, the dihydrochloride salt of BH4, exhibits crystal polymorphism. The structure of BH4 is shown below:
Figure imgf000010_0001
The (6R) form of BH4 is the known biologically active form, however, BH4 is known to be unstable at ambient temperatures.
BH4 is difficult to handle and it was therefore produced and offered as its dihydrochloride salt (Schircks Laboratories, Jona, Switzerland) in ampoules sealed under nitrogen to prevent degradation of the substance due to its hygroscopic nature and sensitivity to oxidation. U.S. Patent No. 4,649,197 discloses that separation of (6R)- and 6(S)-L-erythro-tetrahydrobiopterin dihydrochloride into its diastereomers is difficult due to the poor crystallinity of 6(R.S)-L--ιτythro-tetrahydrobiopterin dihydrochlcride. The European patent number 0 079 574 describes the preparation of tetrahydrobiopterin, wherein a solid tetrahydrobiopterin dihydrochloride is obtained as an intermediate. S. Matsuura et al. describes in Chemistry Letters 1984, pages 735- 738 and Heterocycles, Vol. 23, No. 12, 1985 pages 3115-3120 6(R)- tetrahydrobiopterin dihydrochloride as a crystalline solid in form of colorless needles, which are characterized by X-ray analysis disclosed in J. Biochem. 98, 1341-1348 (1985). An optical rotation of 6.81° was found the crystalline product, which is quite similar to the optical rotation of 6.51 ° reported for a crystalline solid in form of white crystals in example 6 of EP-A2-0 191 335.
Results obtained during development of (6R)-L-erythro- tetrahydrobiopterin dihydrochloride indicated that the compound may exist in different crystalline forms, including polymorphic forms and solvates. It has been found that one crystal polymorph of BH4 is more stable, and is stable to decomposition under ambient conditions. Polymorph Form B
The crystal polymorph that has been found to be the most stable is referred to herein as "form B," or alternatively as "polymorph B."
Polymorph B is a slightly hygroscopic anhydrate with the highest thermodynamic stability above about 20 °C. Furthermore, form B can be easily processed and handled due to its thermal stability, possibility for preparation by targeted conditions, its suitable morphology and particle size. Melting point is near 260 0C (ΔHf > 140 J/g), but no clear melting point can be detected due to decomposition prior and during melting. These outstanding properties renders polymorph form B especially feasible for pharmaceutical applications, which are often prepared at elevated temperatures. Polymorph B can be obtained as a fine powder with a particle size that may range from 0.2 μm to 500 μm.
Form B exhibits an X-ray powder diffraction pattern, expressed in d- values (A) at: 8.7 (vs), 6.9 (w), 5.90 (vw), 5.63 (m), 5.07 (m), 4.76 (m), 4.40 (m), 4.15 (w), 4.00 (s), 3.95 (m), 3.52 (m), 3.44 (w), 3.32 (m), 3.23 (s), 3.17 (w), 3.11 (vs), 3.06 ; w), 2.09 (w), 2.96 (w), 2.94 (m), 2.87 (w), 2.84 (s), 2.82 (m), 2.69 (w), 2.59 (w), 2.44 (w). Figure 1 is a graph of the characteristic X-ray diffiaction pattern exhibited by form B of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride. As used herein, the following the abbreviations in brackets mean: (vs) = very strong intensity; (s) = strong intensity; (m) = medium intensity; (w) = weak intensity; and (vw) = very weak intensity.
Form B can be prepared in very large quantities (e.g., 100 kilo scale) and stored over an extended period of time.
All crystal forms (polymorphs, hydrates and solvates), inclusive crystal form B, can be used for the preparation of the most stable polymorph B. Polymorph B may be obtained by phase equilibration of suspensions of amorphous or other forms, in suitable polar and non aqueous solvents.
Other forms of BH4 can be converted into form B by dispersing the other form of BH4 in a solvent at room temperature, stirring the suspension at ambient temperatures for a time sufficient to produce polymorph form B, thereafter isolating crystalline form B and removing the solvent from the isolated form B. Ambient temperatures, as used herein, mean temperatures in a range from O °C to 60 0C, preferably 15 0C to 40 0C. The applied temperature may be changed during treatment and stirring by decreasing the temperature stepwise or continuously. Suitable solvents for the conversion of other forms to form B include but are not limited to, methanol, ethanol, isopropanol, other C3- and C4-alcohols, acetic acid, acetonitrile, tetrahydrofurane, methy-t-butyl ether, 1 ,4-dioxane, ethyl acetate, isopropyl acetate, other C3-C6-acetates, methyl ethyl ketone and other methyl-C3-C5 alkyl -ketones. The time to complete phase equilibration may be up to 30 hours and preferably up to 20 hours or less than 20 hours. Polymorph B may also be obtained by crystallisation from solvent mixtures containing up to about 5% water, especially from mixtures of ethanol, acetic acid and water. It has been found that polymorph form B of (6R)-L-erythro- tetrahydrobiopterin dihydrochloride can be prepared by dissolution, optionally at elevated temperatures, preferably of a solid lower energy form than form B of of form B of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride in a solvent mixture comprising ethanol, acetic acid and water, addition of seeds to the solution, cooling the obtained suspension and isolation of the formed crystals. Dissolution may be carried out at room temperature or up to 70 0C, preferably up to 50 0C. There may be used the final solvent mixture for dissolution or the starting material may be first dissolved in water and the other solvents may than be added both or one after the other solvent. The composition of the solvent mixture may comprise a volume ratio of water : acetic acid : tetrahydrofuran of 1 : 3: 2 to 1 : 9: 4 and preferably 1 : 5: 4. The solution is preferably stirred. Cooling may mean temperatures down to -40 °C to 0 °C, preferably down to 10 0C to 30 0C. Suitable seeds are polymorph form B from another batch or crystals having a similar or identical morphology. After isolation, the crystalline form B can be washed with a non-solvent such as acetone or tetrahydrofurane and dried in usual manner.
Polymorph B may also be obtained by crystallization from aqueous solutions through the addition of non-solvents such as methanol, ethanol and acetic acid. The crystallisation and isolation procedure can be advantageously carried out at room temperature without cooling the solution. This process is therefore very suitable to be carried out at an industrial scale. In one embodiment of the compositions and methods described herein, a composition including polymorph form B of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride is prepared by dissolution of a solid form other than form B or of form B of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride in water at ambient temperatures, adding a non-solvent in an amount sufficient to form a suspension, optionally stirring the suspension for a certain time, and thereafter isolation of the formed crystals. The composition is further modified into a pharmaceutical composition as described below.
The concentration of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride in the aqueous solution may be from 10 to 80 percent by weight, more preferably. from 20 to 60 percent by weight, by reference to the solution. Preferred non-solvents (i.e., solvents useful in preparing suspensions of BH4) are methanol, ethanol and acetic acid. The non-solvent may be added to the aqueous solution. More preferably, the aqueous solution is added to the non-solvent. The stirring time after formation of the suspension may be up to 30 hours and preferably up to 20 hours or lesε than 20 hours. Isolation by filtration and drying u earned out in known manner as desz.nbsd above.
Polymorph form B is a very stable crystalline form, that can be easily filtered off, dried and ground to particle sizes desired for pharmaceutical formulations. These outstanding properties renders polymorph form B especially feasible for pharmaceutical application.
III. Stable Pharmaceutical Formulations
Pharmaceutical formulations may initially include a stable crystalline form of tetrahydrobiopterin, or a precursor or derivative or analog thereof, with a pharmaceutically acceptable carrier. The stable formulation of the invention preferably contains one or more of the following additional ingredients that improve the stability or other characteristics of the formulation: binder, disintegration agent, acidic antioxidant, or lubricant or combinations thereof. Preferably a stable tablet formulation includes a binder and disintegration agent, optionally with an acidic antioxidant, and optionally further including a lubricant. The initial amount of a crystalline polymorph of (6R)-L-erythro- tetrahydrobiopterin used to prepare the formulation may be, for example, in the range of about 30 wt% to about 40 wt% of the formulation, or in the range of about 32 wt% to about 35 wt%, or at about 33 wt%. Binders assist in maintaining the tablet formulation. In some cases, anhydrous binders are used to preserve the anhydrous state of polymorph B. In some cases, the binder may act as a drying agent. Exemplary binders include anhydrous dibasic calcium phosphate and its monohydrate.
Exemplary concentrations of the binder in a stable tablet formulation of the present invention are between about 1 wt% to about 5 wt%. Particularly contemplated concentrations are between about 1.5 and 3 wt%. Also contemplated are concentrations of binder of at least about 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, and 3.0 wt%, or concentrations up to about 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3. 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, and 5.0 wt%. The weight ratio of binder to tetrahydrobiopteπn in a stable tablet formulation of the present invention is, for example, in the range of about 1 : 10 to about 1 :20. Also contemplated are weight ratios of abou\ 1 : 10.25, 1:10.5, 1.10.75, 1 :11, 1 :11.25, 1 :1 1.5, 1 :11.75, 1 :12, 1:12.25, 1 :12.5, 1 :12.75, 1 :13, 1:13.25, 1 :13.5, 1 :13.75, 1:14, 1 :14.25, 1 :14.5, 1:14.75, 1 -15, 1 :15.25, 1 :15.5, 1 :15.75, 1 :16, 1 :16.25, 1:16.5, 1:16.75, 1:17, 1 :17.25, 1 :17.5, 1:17.75, 1 :18, 1 :18.25, 1:18.5, 1 :18.75, 1 :19, 1:19.25, 1:19.5, and 1:19.75.
Disintegration agents assist in rapid disintegration of solid formulations by absorbing water and expanding. Exemplary disintegration agents include polyvinylpyrrolidone (PVP, e.g. sold under the name POVIDONE), a cross- linked form of povidone (CPVP, e.g. sold under the name CROSPOVIDONE), a cross-linked form of sodium carboxymethylcellulose (NaCMC, e.g. sold under the name AC-DI-SOL), other modified celluloses, and modified starch. Tablets formulated with CPVP exhibited much more rapid disintegration than tablets formulated with PVP. Exemplary concentrations of the disintegration agent in a stable table formulation of the present invention are between about 1 wt% to about 20 wt%. Particularly contemplated concentrations are between about 3 wt% and about 10 wt%. Also contemplated are concentrations of disintegration of at least about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, and 3.0 wt%, or concentrations up to about 4.0, 4.1, 4.2, 4.3, 4.4, 4.55 4.6, 4.7, 4.8, 4.9, 5.0, 5.2, 5.4, 5.6, 5.7, 5.8, 6.0, 6.25, 6.5, 6.75, 8.0, 8.25, 8.5, 8.75, 9.0, 9.25, 9.5, 9.75, and 10.0 wt%. The weight ratio of disintegration agent to tetrahydrobiopterin in a stable tablet formulation of the present invention is, for example, in the range of about 1 :5 to about 1 :10. Also contemplated are weight ratios of about 1 :5.25, 1 :5.5, 1:5.75, 1:6.0, 1:6.25, 1 :6.5, 1 :6.75, 1:7.0, 1 :7.25, 1:7.5, 1 :7.75, 1 :8.0, 1 :8.25, 1:8.5, 1:8.75, 1 :9.0, 1 :9.25, 1:9.5, and 1:9.75.
Antioxidants may be included and help stabilize the tetrahydrobiopterin product, especially after dissolution. Low pH aqueous solutions of API are more stable than are solutions at high pH. Exemplary acidic antioxidants include ascorbic acid, fatty acid esters of ascorbic acid such as ascorbyl palmitate and ascorbyl stearate, and salts of ascorbic acid such as sodium, calcium, or potassium ascorbate. Non-acidic antioxidants may also be u:-wά in the stable tablet formulations. Nenlimiting examples of non-acidic antioxidants ΪΛeiuάe bαa-carcterie. alpha- tocopherol. Acidic additives may be added to enhance stability of tlie tabiet formulation, including citric acid or malic acid. Exemplary concentrations of the antioxidant in a stable table formulation of the present invention are between about 1 wt% and about 3 wt%. Particularly contemplated concentrations are at least about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, and 2.0 wt%, or concentrations up to about 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, and 3.0 wt%. The weight ratio of antioxidant to tetrahydrobiopterin in a stable tablet formulation of the present invention is, for example, in the range of about 1 :5 to 1 :30. Also contemplated are weight ratios of about 1 :5.5, 1 :6, 1 :6.5, 1 :7, 1 :7.5, 1 :8, 1:8.5, 1:9, 1:9.5, 1:10, 1:10.5, 1 :11, 1:11.5, 1 :12, 1 :12.5, 1:13, 1 :13.5, 1:14, 1:14.5, 1 :15, 1 :15.5, 1:16, 1 :16.5, 1:17, 1:17.5, 1 :18, 1:18.5, 1:19, 1:19.5, 1:20, 1 :20.5, 1:21, 1 :21.5, 1:22, 1 :22.5, 1:23, 1 :23.5, 1 :24, 1:24.5, 1 :25, 1 :25.5, 1:26, 1 :26.5, 1:27, 1 :27.5, 1 :28, 1 :28.5, 1 :29, and 1 :29.5.
In Schirk's Laboratory tablets, ascorbic acid is present at a ratio of 1 :1 to BH4. In contrast, the concentration of ascorbic acid in the stable formulations of the invention is far lower, e.g. a weight ratio (mg/mg) of 1 :20 of ascorbic acid to BH4. Thus, the invention also contemplates formulations comprising ascorbic acid at a ratio to BH4 of less than 1 :1, e.g. 1 :2, 1:3, 1 :4, 1 :5, 1:6, 1 :7, 1 :8, 1 :9, 1 :10, 1 :11, 1:12, 1 :13, 1:14, 1 :15, 1 :16, 1 :17, 1 : 18 or 1 : 19, preferably a ratio of less than 1 :10. Lubricants improve stability, hardness and uniformity of solid formulations. Exemplary lubricants include stearyl fumarate and magnesium stearate.
Exemplary concentrations of the lubricant in a stable tablet formulation of the present invention are between about 0.1 wt% and about 2 wt%. Particularly contemplated concentrations are between about 0.5 and 1 wt%. Also contemplated are concentrations of lubricant of at least about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, and 1.0 wt%, or concentrations up to about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, and 2.0 wt%. The weight ratio of lubricant to tetrahydrobiopterin in a stable tablet formulation of the present invention is, for example, in the range of about 1 :25 to 1 65. Also contemplated are weight ratios of about 1 :26, 1:27, 1 :28, 1:29, 1 :30, 1 :31, 1 :32, 1:33, 1 :34, 1 :35, 1 :36, 1 :37, 1 :38, 1:39, 1 :40, 1 :4 ! , 1 :4?, 1 :43, 1 :44. 1 :45, 1 :46, [A■ ''\ 1:48, 1 :49, 1:50, 1 :51, 1 :52, 1 :53, 1:54, 1 :55, ϊ :5ύ. 1 :57, 1 :5?:. 1 :59, 1:60, 1 :61, i :62, 1 :63, L64, and 1 :65. llie stable solid formulation may op(iona3]> include othei therapeutic agents suitable for the condition to be treated, e.g. folates, including folate precursors, folic acids, or folate derivatives; and/or arginine; and/or vitamins, such as vitamin C and/or vitamin B2 (riboflavin) and/or vitamin B 12; and/or neurotransmitter precursors such as L-dopa or carbidopa; and/or 5-hydroxytryptophan.
Exemplary folates, including folate precursors, folic acids, or folate derivatives, are disclosed in U.S. Patent Nos. 6,011,040 and 6,544,994, both of which are incorporated herein by reference, and include folic acid (pteroylmonoglutamate), dihydrofolic acid, tetrahydrofolic acid, 5-methyltetrahydrofolic acid, 5,10- methylenetetrahydrofolic acid, 5,10-methenyltetrahydrofolic acid, 5,10- formiminotetrahydrofolic acid, 5-formyltetrahydrofolic acid (leucovorin), 10- formyltetrahydrofolic acid, 10-methyltetrahydrofolic acid, one or more of the folylpolyglutamates, compounds in which the pyrazine ring of the pterin moiety of folic acid or of the folylpolyglutamates is reduced to give dihydrofolates or tetrahydrofolates, or derivatives of all the preceding compounds in which the N- 5 or N-IO positions carry one carbon units at various levels of oxidation, or pharmaceutically compatible salts thereof, or a combination of two or more thereof. Exemplary tetrahydrofolates include 5-formyl-(6S)-tetrahydrofolic acid, 5-methyl- (6S)-tetrahydrofolic acid, 5,10-methylene-(6R)-tetrahydrofolic acid, 5,10-methenyl- (6R)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid, 5-formimino-(6S)- tetrahydrofolic acid or (6S)-tetrahydrofolic acid, and pharmaceutically acceptable salts thereof. Exemplary salts include sodium, potassium, calcium or ammonium salts. Exemplary relative weight ratios of BH4 to folates to arginine may be from about 1:10:10 to about 10:1 :1.
Optionally the stable formulations of the invention can also comprise other excipients such as mannitol, hydroxyl propyl cellulose, microcrystalline cellulose, or other non-reducing sugars such as sucrose, trehalose, melezitose, planteose, and raffinose. Reducing sugars may react with BH4.
Pharmaceutically acceptable ingredients for manufacturing SOJ V formulations for oral administration may be incorporated, for example, b> ad' i living the components and optionally finely dividing them, and then tilling capsule^, composed for example from hard or soft gelatin, compressing tablets, pills or troches. Coatings may be applied after compression to form pills.
Pharmaceutically acceptable ingredients are well known for the various types of formulation and may be for example binders such as natural or synthetic polymers, excipients, lubricants, surfactants, sweetening and flavouring agents, coating materials, preservatives, dyes, thickeners, adjuvants, antimicrobial agents, antioxidants and carriers for the various formulation types. Nonlimiting examples of binders useful in a composition described herein include gum tragacanth, acacia, starch, gelatine, and biological degradable polymers such as homo- or co-polyesters of dicarboxylic acids, alkylene glycols, polyalkylene glycols and/or aliphatic hydroxyl carboxylic acids; homo- or co-polyamides of dicarboxylic acids, alkylene diamines, and/or aliphatic amino carboxylic acids; corresponding polyester-polyamide-co- polymers, polyanhydrides, polyorthoesters, polyphosphazene and polycarbonates. The biological degradable polymers may be linear, branched or crosslinked. Specific examples are poly-glycolic acid, poly-lactic acid, and poly-d,l-lactide/glycolide. Other examples for polymers are water-soluble polymers such as polyoxaalkylenes (polyoxaethylene, polyoxapropylene and mixed polymers thereof, poly-acrylamides and hydroxylalkylated polyacrylamides, poly-maleic acid and esters or -amides thereof, poly-acrylic acid and esters or -amides thereof, poly-vinylalcohol und esters or -ethers thereof, poly-vinylimidazole, poly- vinyl pyrrolidon, und natural polymers like chitosan.
Nonlimiting examples of excipients useful in a composition described herein include phosphates such as dicalcium phosphate. Nonlimiting examples of lubricants use in a composition described herein include natural or synthetic oils, fats, waxes, or fatty acid salts such as magnesium stearate.
Surfactants for use in a composition described herein can be anionic, anionic, amphoteric or neutral. Nonlimiting examples of surfactants useful in a composition described herein include lecithin, phospholipids, octyl sulfate, decyl sulfate, dodecyl sulfate, tetradecy! su lfate, hexadecyl sulfate and octadecyl sulfate, Na oleate or Na caprate, l-acylar.iirj', orαa!ie-2-sulfonic acids, such as 1- octanoylaminoethane-2-sulfonic acici. l-decanoylaminoethane-2-sulfonic acid, 1- dodecanoylaminoethane-2-sulfonic acid, 1 -tetradecanoylaminoethane-2-sulfonic acid, l-hexadecanoylaminoethane-2-sulfonic acid, and l-octadecanoylaminoethane-2- sulfonic acid, and taurocholic acid and taurodeoxycholic acid, bile acids and their salts, such as cholic acid, deoxycholic acid and sodium glycocholates, sodium caprate or sodium laurate, sodium oleate, sodium lauryl sulphate, sodium cetyl sulphate, sulfated castor oil and sodium dioctylsulfosuccinate, cocamidopropylbetaine and laurylbetaine, fatty alcohols, cholesterols, glycerol mono- or -distearate, glycerol mono- or -dioleate and glycerol mono- or -dipalmitate, and polyoxyethylene stearate.
Nonlimiting examples of sweetening agents useful in a composition described herein include sucrose, fructose, lactose or aspartame. Nonlimiting examples of flavoring agents for use in a composition described herein include peppermint, oil of wintergreen or fruit flavors such as cherry or orange flavor.
Nonlimiting examples of coating materials for use in a composition described herein include gelatin, wax, shellac, sugar or other biological degradable polymers. Nonlimiting examples of preservatives for use in a composition described herein include methyl or propylparabens, sorbic acid, chlorobutanol, phenol and thimerosal.
The polymorph described herein may also be formulated as effervescent tablet or powder, which disintegrate in an aqueous environment to provide a drinking solution. Slow release formulations may also be prepared from the polymorph described herein in order to achieve a controlled release of the active agent in contact with the body fluids in the gastro iniestinal tract, and to provide a substantial constant and effective level of the active agent in the blood plasma. The crystal form may be embedded for this purpose in a polymer matrix of a biological degradable polymer, a water-soluble polymer or a mixture of both, and optionally suitable surfactants. Embedding can mean in this context the incorporation of micro- particles in a matrix of polymers. Controlled release formulations are also obtained through encapsulation of dispersed micro-particles or emulsified micro-droplets via known dispersion or emulsion coating technologies. The BH4 used m a composition described herein is preferably formulated as a dihydrochloiiie salt, liov.cev. ύ is contemplated that other salt forms of BHA possess the desired biological activity, and consequently, ether salt forms of BH4 can be used. Specifically, BI/4 sails wi!h inorganic or organic acids are preferred. Nonlimiting examples of alternative BW salts forms includes BH4 salts of acetic acid, citric acid, oxalic acid, tartaric acid, fumaric acid, and mandelic acid.
Pharmaceutically acceptable base addition salts may be formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Pharmaceutically acceptable salts of compounds may also be prepared with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are also possible. Examples of metals used as cations are sodium, potassium, magnesium, ammonium, calcium, or ferric, and the like. Examples of suitable amines include isopropylamine, trimethylamine, histidine, N.N' dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N methylglucamine, and procaine. Pharmaceutically acceptable acid addition salts include inorganic or organic acid salts. Examples of suitable acid salts include the hydrochlorides, acetates, citrates, salicylates, nitrates, phosphates. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art and include, for example, acetic, citric, oxalic, tartaric, or mandelic acids, hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fumaπc acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4 aminosalicylic acid, 2 phenoxybenzoic acid, 2 acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with amino acids, such as the 20 alpha amino acids involved in the synthesis of proteins in nature, for example glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2 hydroxyethanesulfonic acid, ethane 1 ,2 disulfonic acid, benzenesulfomc acid, 4 methylbenzenesulfoc acid, naphthalene 2 sulfonic 8cid, naphthalene : ,5 dis'ilfonic icid. 2 or J phoMVojiycerate. glucose ^ ρbυ>phaιe, N eyclohεxylsulfdniic acid (with * the formation of L-ychimates), or with othei acid organic compounds, such as ascorbic acid. The stable formulations of the invention may be provided, e.g. as tablets or pills or capsules in HDPE bottles provided with a dessicant capsule or pouch; or in foil-on-foil blister packaging, or in blister packaging comprising see- through polymer film, if commercially desirable.
The phrase "pharmaceutically or pharmacologically acceptable" refers to molecular entities and compositions that do not produce adverse, allergic, or other untoward reactions when administered to an animal or a human. As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the therapeutic compositions, its use in therapeutic compositions is contemplated. Supplementary active ingredients also can be incorporated into the compositions.
As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients also can be incorporated into the compositions. It will be appreciated that the pharmaceutical compositions and treatment methods of the invention may be useful in fields of human medicine and veterinary medicine. Thus the subject to be treated may be a mammal, preferably human or other animal. For veterinary purposes, subjects include for example, farm animals including cows, sheep, pigs, horses and goats, companion animals su ;h as dogs and cii-s, exotic and/or zoo animals, laboratory animals including mice rats", rabbits. ^ni;?e.: pigs ai;d hamsters; and poultry such as chickens, turkey ducks and geese.
JV-. Tr-eatiyeiϊt Methods Using Stable Formulations
The stable foπnulations of the invention may be used for treatment of conditions associated with elevated phenylalanine levels or decreased tyrosine or tryptophan levels, which may be caused, for example, by reduced phenylalanine hydroxylase, tyrosine hydroxylase, or tryptophan hydroxylase activity. Conditions associated v.ϊth elevated phenylalanine levels specifically include phenylketonuria, both mild and classic, and hyperphenylalaninemia as described herein, and exemplary patient populations include the patient subgroups described herein as well as any other patient exhibiting phenylalanine levels above normal. Conditions associated with decreased tyrosine or tryptophan levels include neurotransmitter deficiency, neurological and psychiatric disorders such as Parkinson's, dystonia, spinocerebellar degeneration, pain, fatigue, depression, other affective disorders and schizophrenia. The stable formulations may also be used for treating patients suffering from BH4 deficiency, e.g., due to a defect in the pathway for its synthesis, including but not limited to dopa-responsive dystonia (DRD), sepiapterin reductase (SR) deficiency, or dihydropteridine reductase (DHPR) deficiency.
Suitable subjects for treatment with the stable formulations of the invention include subjects with an elevated plasma Phe concentration in the absence of the therapeutic, e.g. greater than 1800 μM/L, or greater than 1600 μM, greater than 1400 μM, greater than 1200 μM, greater than 1000 μM, greater than 800 μM, or greater than 600 μM, greater than 420 μM, greater than 300 μM, greater than 200 μM, or greater than 180 μM. Mild PKU is generally classified as plasma Phe concentrations of up to 600μM/L, moderate PKU as plasma Phe concentrations of between 600μM/L to about 1200μM/L and classic or severe PKU as plasma Phe concentrations that are greater than 1200μM/L. Preferably treatment with the stable formulations alone or with protein-restricted diet decreases the plasma phenylalanine concentration of the subject to less than 600 μM, or less than 500 μM, υr 360 μM ± 15 μM or less, or less than 200 μM, or less than 100 μM. Other suitable subjects include subjects diagnoses εs having a reduced phenylalanine hydroxylase (P -S. H; activity. Redu'.-e.J PAH activity rray result from a mutation in the PΛH cnz>π-e. ior example, a mυ'utk r IΛ
Figure imgf000022_0001
analytic domain of PAH or one or more ;uut:ι.ionv selected from the group consisting of F39L, L48S, I65T, R68S, A1C4D, SI IOC. D129G, E178G, V 190A, P2J IT, R241C, R261Q, A300S, L308F, A313T, K320N, A373T, V388M E390G, A395P, P407S, and Y414C; or subjects that are pregnant- females, females of child-bearing age that are contemplating pregnancy, or infants between 0 and 3 years of age, or 0-2, 0-1.5 or 0-1; or subjects diagnosed as unresponsive within 24 hours to a single-dose BH4 loading test or a multiple dose loading test, such as a 4-dose or 7-day loading test. Exemplary patient populations and exemplary 8H4 loading tests are described in Int'l. Publication No. WO 2005/049000, incorporated herein by reference in its entirety.
U.S. Patent Nos. 4,752,573; 4,758,571; 4,774,244; 4,920,122; 5,753,656; 5,922,713; 5,874,433; 5,945,452; 6,274,581; 6,410,535; 6,441,038; 6,544,994; and U.S. Patent Publications US 20020187958; US 20020106645; US 2002/0076782; US 20030032616(each incorporated herein by reference) each describe methods of administering BH4 compositions for non-PKU treatments. Each of those patents is incorporated herein by reference as providing a general teaching of methods of administering BH4 compositions known to those of skill in the art, that may be adapted for the treatment as described herein.
While individual needs vary, determination of optimal ranges of effective amounts of each component is within the skill of the art. Typical dosages of the BH4 comprise about 1 to about 20 mg/kg body weight per day, which will usually amount to about 5 (1 mg/kg x 5kg body weight) to 3000 mg/day (30mg/kg x 100kg body weight). While continuous, daily administration is contemplated, for HPA it may be desirable to cease the BH4 therapy when the symptoms of Phe levels are reduced to below a certain threshold level. Of course, the therapy may be reinitiated in the event that Phe levels rise again. Appropriate dosages may be ascertained through the use of established assays for determining blood levels of Phe in conjunction with relevant dose response data.
In preferred embodiments, it is contemplated that the methods of the present invention will provide to a patient in need thereof, a daily dose of between about 10 mg/kg to about 20 mg/kg of BH4. Of course, one skilled in the art may adjusf this dose up or dov/n depending on the efficacy being achieved by the administration. The daily dose may be administered \n <x single Jose, or alternatively. may be administered in multiple doses at conveniently spaced intervals. In exemplary embodiments, the daily dose may be 1 mg/kg, 2 mg/kg, 3 mg/kg, 4 tog/kg, 5 mg/kg, 6 mg/kg, 7 mg/kg, 8 mg/kg, 9 mg/kg, 10 mg/kg, 11 -mg/kg, 12 mg/kg, 13 mg/kg, 14 mg/kg, 15 mg/kg, 16 mg/kg, 17 mg/kg, 18 mg/kg, 19 mg/kg, 20 mg/kg, 22 mg/kg, 24 mg/kg, 26 mg/kg, 28 mg/kg, 30 mg/kg, 32 mg/kg, 34 mg/kg, 36 mg/kg, 38 mg/kg, 40 mg/kg, 42 mg/kg, 44 mg/kg, 46 mg/kg, 48 mg/kg, 50 mg/kg, or more mg/kg.
The invention further contemplates that stable formulations of the invention may be used for treatment of subjects suffering from conditions that would benefit from enhancement of nitric oxide synthase activity and patients suffering from vascular diseases, ischemic or inflammatory diseases, or insulin resistance. The treatment may, for example alleviate a deficiency in nitric oxide synthase activity or may, for example provide an increase in nitric oxide synthase activity over normal levels. It has been suggested that a patient suffering from a deficiency in nitric oxide synthase activity would benefit from co-treatment with folates, including folate precursors, folic acids, or folate derivatives. Nitric oxide is constitutively produced by vascular endothelial cells where it plays a key physiological role in the regulation of blood pressure and vascular tone. It has been suggested that a deficiency in nitric oxide bioactivity is involved in the pathogenesis of vascular dysfunctions, including coronary artery disease, atherosclerosis of any arteries, including coronary, carotid, cerebral, or peripheral vascular arteries, ischemia-reperfusion injury, hypertension, diabetes, diabetic vasculopathy, cardiovascular disease, peripheral vascular disease, or neurodegenerative conditions stemming from ischemia and/or inflammation, such as stroke, and that such pathogenesis includes damaged endothelium, insufficient oxygen flow to organs and tissues, elevated systemic vascular resistance (high blood pressure), vascular smooth muscle proliferation, progression of vascular stenosis (narrowing) and inflammation. Thus, treatment of any of these conditions is contemplated according to methods of the invention.
It has also been suggested that the enhancement of nitric oxide synthase activity also results in reduction of elevated superoxide levels, increased insulin sensitivity, and reduction in vascular djsl'iifictiυn associated with .insulin resistance, as described in U.S. Patent No. ή,4 i.O. :'>;"!- 5, incorporated herein by reference. Thus, treatment of diabetes (type ϊ or Iy pe ΪI), hyperinsuiiϊiemia, or insulin . resistance is contemplated according to the invention. Diseases having vascular dysfunction associated with insulin resistance include those caused by insulin resistance or aggravated by insulin resistance, or those for which cure is retarded by insulin resistance, such as hypertension, hyperlipidemia, arteriosclerosis, coronary vasoconstrictive angina, effort angina, cerebrovascular constrictive lesion, cerebrovascular insufficiency, cerebral vasospasm, peripheral circulation disorder, coronary arteriorestenosis following percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass grafting (CABG), obesity, insulin-independent diabetes, hyperinsulinemia, lipid metabolism abnormality, coronary arteriosclerotic heart diseases or the like so far as they are associated with insulin resistance. It is contemplated that when administered to patients with these diseases, BH4 can prevent or treat these diseases by activating the functions of NOS, increasing NO production and suppressing the production of active oxygen species to improve disorders of vascular endothelial cells. It is understood that the suitable dose of a composition according to the present invention will depend upon the age, health and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired (i.e., the amount of decrease in plasma Phe concentration desired). The frequency of dosing also is dependent on pharmacodynamic effects on Phe levels. If the effect lasts for 24 hours from a single dose. However, the most preferred dosage can be tailored to the individual subject, as is understood and determinablc by one of skill in the art, without undue experimentation. This typically involves adjustment of a standard dose, e.g., reduction of the dose if the patient has a low body weight. The frequency of BH4 dosing will depend on the pharmacokinetic parameters of the agent and the routes of administration. The optimal pharmaceutical formulation will be determined by one of skill in the art depending on the route of administration and the desired dosage. See for example Remington's Pharmaceutical Sciences. 18th Ed. (1990, Mack Publ. Co, Easton PΛ 18042) pp 1435 1712, incorporated herein by reference. Such formulation!* may influence the physical state, ctahiϋty, rate of in vivo release and rate of in \ ivo ci idiitncv of die administered - rigenK-. Depending un the
Figure imgf000025_0001
α ? '.,i'.Λk dose1 may be calculated according to body weight, body surface areas oi org-'n size. Further refinement of the calculations necessary to determine the appropriate treatment dose is routinely made by those of ordinary skill in the art without undue experimentation, especially in light of the dosage information and assays disclosed herein as well as the pharmacokinetic data observed in animals or human clinical trials.
The final dosage regimen will be determined by the attending physician, considering factors which modify the action of drugs, e.g., the drug's specific activity, severity of the damage and the responsiveness of the patient, the age, condition, body weight, sex and diet of the patient, the severity of any infection, time of administration and other clinical factors. As studies are conducted, further information will emerge regarding appropriate dosage levels and duration of treatment for specific diseases and conditions.
V. Combination therapy Certain methods of the invention involve the combined use of the stable formulations of the invention and one or more other therapeutic agents.
In such combination therapy, administration of the stable formulations of the invention may be concurrent with or may precede or follow the administration of the second therapeutic agent, e.g. by intervals ranging from minutes to hours, so long as both agents are able to exert their therapeutic effect at overlapping time periods. Thus, the invention contemplates the stable formulations of the invention for use with a second therapeutic agent. The invention also contemplates use of a second therapeutic agent in preparation of a medicament for administration with the stable tetrahydrobiopterin, precursor, derivative or analog formulations of the invention.
Tetrahydrobiopterin therapy may be combined with dietary protein restriction to effect a therapeutic outcome in patients with various forms of HPA. For example, one could administer to the subject the BH4 composition and a low- phenylalanine medical protein composition in a combined amount effective to produce the desired therapeutic outcome (/. e., a lowering of plasma Phe concentration and/cr the ab.'lity tc tolerate greater amounts of Phe/protein intake without producing a concomitant increase in plasma Phe concentrations). This process may involve administering the BH4 composition and the dietary protein therapeutic composition at the same lime. This may be achieved by administering a single composition or pharmacological protein formulation that includes all of the dietary protein requirements and also includes the BH4 within said protein formulation. Alternatively, the dietary protein (supplement or normal protein meal) is taken at about the same time as a pharmacological formulation (tablet, injection or drink) of BH4. In other alternatives, the BH4 treatment may precede or follow the dietary protein therapy by intervals ranging from minutes to hours. In embodiments where the protein and the BH4 compositions are administered separately, one would generally ensure that a significant period of time did not expire between the time of each delivery, such that the BH4 will still be able to exert an advantageously effect on the patient. In such instances, it is contemplated that one would administer the BH4 within about 2-6 hours (before or after) of the dietary protein intake, with a delay time of only about 1 hour being most preferred. In certain embodiments, it is contemplated that the BH4 therapy will be a continuous therapy where a daily dose of BH4 is administered to the patient indefinitely. In other situations, e.g., in pregnant women having only the milder forms of PKU and HPA, it may be that the BH4 therapy is only continued for as long as the woman is pregnant and/or breast feeding. Further, in addition to therapies based solely on the delivery of BH4 and dietary protein regulation, the methods of the present invention also contemplate combination therapy with a third composition that specifically targets one or more of the symptoms of HPA. For example, it is known that the deficit in tyrosine caused by HPA results in a deficiency in neurotransmitters dopamine and serotonin. Thus, in the context of the present invention, it is contemplated that BH4 and dietary protein based methods could be further combined with administration of L-dopa, carbidopa and 5-hydroxytryptophan neurotransmitters to correct the defects that result from decreased amounts of tyrosine in the diet.
In addition, gene therapy with both PAH (Christensen et ah, MoI. Gent. And MetaboL 76: 313-318, 2002; Christensen et al, Gene Therapy, 7:1971 1978, 2000) and phony! alanine ammonia-lyase (PAL Liu et al.,-Arts: Cells. Blood. Subs and Immoo' . Bioiech. 30(4)243-257, 2002) has been contemplated by those of skill in the art. Such gene therapy techniques could be used in combination with the combined BH4/dietary protein restriction based therapies of the invention. In further combination therapies, it is contemplated that phenylase may be provided as an injectable enzyme to destroy lower Phe concentrations in the patient. As the administration of phenylase would not generate tyrosine (unlike administration of PAH), such treatment will still result in tyrosine being an essential amino acid for such patients. Therefore dietary supplementation with tyrosine may be desirable for patients receiving phenylase in combination with the BH4 therapy.
VII. Examples
The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.
EXAMPLE 1 Preparation of Stabilized Crystallized Form of BH4 lnt'1. Publication No. WO 2005/065018, incorporated herein by reference in its entirety, describes X ray and Raman spectra studies to characterize the polymorphs, including hydrates or solvates, of BH4, as well as exemplary crystallization conditions under which the polymorphs can be prepared. Int'l. Publication No. WO 2005/049000, incorporated herein by reference in its entirety, describes various patient populations for which BH4 treatment is suitable and describes methods for treating such subjects with BH4. Int'l Publication No. WO2005/0496 ', 4 ' incorporated herein by reference in its entirety, describe method? of - s/ntnesizing BiJ i.
'the references cited herein throughout, to the extent that they pro-'ide exemplary procedural or other details supplementary to those set forth herein; are all specifically incorporated herein by reference. EXAMPLE 2
Stable Tablet Formulation of Tetrahydrobiopterin
Three tablet formulations were prepared by mixing the ingredients shown in Table J as described in detail below.
Table I
Formulation I Formulation Il Formulation III Ingredient (wt %) (wt %) (wt %) R-L-erythro-5, 6, 7, 8-tetrahydrobiopterin dihydrochloride salt, polymorph B 33.33 33.33 33.33
(Active Ingredient)
D-Mannhol ^ % ^ ^
(Taste Masking) Dibasic Calcium Phosphate, Anhydrous
2.18 2.18 (Binder)
Hydroxypropyl Cellulose
3.63 4.5 (Disintegrant)
Polyvinylpyrrolidone
4.50 (Disintegrant)
Ascorbic acid
1.67 1.67 (Stabilizer)
Riboflavin
0.01 0.01 0.01 (Coloring Agent)
Sodium Stearyl Fumarate
0.75 0.75 (Lubricant)
For each formulation in Table I, twelve kilogram batches were prepared by first charging 4 kg of 6R-L-etythro-5, 6, 7, 8-tetrahydrobiopterin drhydrochloride salt (SAPROPTERTN Hydrochloride, available from Daiichi Suntory Phaπuc. Co., Ltd., Japan to a blender and blending the BH4 for 10 minutes at 25 evolutions per minute (RPM). Then 6.91 kg of D-Mannitoi (PEARUTOL, available from R oquette America, rnc. , Keokuk; Iowa) was added to the blender and the mixture was allowed to blend for an additional ] 0 minutes at 25 RPM. Then 260 grams of Anhydrous Dibasic Calcium Phosphate (available from Mallinckrodt Bakεr,. Inc., Phillipsburg, New Jersey) and (a) in Formulation I, 436 grams of Hydroxypropyl Cellulose and 104 grams were added to the blender, (b) in Formulation II 540 grams of Hydroxypropyl Cellulose was added to the blender; (c) in Formulation III, 540 grams of Polyvinylpyrrolidone (KOLLIDON CL, available from BASF Corporation, Florham Park, New Jersey) were added to the blender, and the mixture was allowed to blend for an additional 10 minutes at 25 RPM. To the bender 200 grams of Ascorbic Acid and 120 grams of Ribofloavin were added to the blender and the mixture was allowed to blend for 3 minutes at 25 RPM. The Sodium Stearyl Fumarate lubricant (PRUV, available from Penwest Pharmaceuticals Co., Danbury, Connecticut) was filtered through a 25 mesh stainless steel screen and into a bag, and the blender was then charged with 9 kg of the screened Sodium Stearyl Fumarate, and the resulting mixture was allowed to blend for 5 minutes at 25 RPM. The blended mixture of each formulation were then removed from the blender, and three samples of each formulation were collected for the preparation of a 150 mg, a 300 mg, and a 600 mg tablets. For each formulation, the tablet samples (150 mg, 300 mg, and 600 mg) were placed in a tablet press (available from Jenn- Chiang Mahinery Co., Ltd., Taiwan, R.O.C.) wherein the parameters of the tablet press were set to provide tablets with a thickness in the range of 4.5 to 5.5 millimeters, and a target hardness of 7 KP.
The resulting tablets were then analyzed to determine the stability of the formulations. The stability of the formulations was studied for a change in
10 appearance over time by a visual inspection at different intervals, for disintegration of the foπnulation utilizing the United States Pharmacopeia recommendations no. 701, and foi a chemical change by assaying the components of the formulations. The-, results of the stability tests are summarized below in Table II.
n Table II
^ on
Figure imgf000030_0001
5 min 20
Disintegration 5 min 40 sec 8 min 4 sec sec
Chemical
97.10% 97.90% 98.2 100.7
Assay
II Off white Broken chip Broken chip Broken round on some on some chip on
Tablets tablets. tablets. some
Light yellow Light yellow tablets.
Appearance spots spots Light (diameter 1- (diameter 1- brown
2 mm) on 2 mm) on spots the off white the off white (diameter round round 1-2 mm) on tablets. tablets the dark brown tablets
4 min 10 4 min 38 sec 6 min 52 sec
Disintegration sec
Chemical 102.70% 100.00% 100.2 97.4 Assay
III Rough Rough Rough
Color is surface, and surface, and surface,
Appearance off white color is light color is light and color is yellow yellow yellow
1 min 52
Disintegration 35 sec 58 sec sec
Chemical
100.20% 102.90% 97.4 99.8
Assay
The stability tests show that tablet Formulation HI is more stable t&t the other formulations of BH4. Each of the pharmaceutical preparations are useful fermn'aijons for the delivery of BH4. Formulation III exhibilod better sfaoility tlihi Formulations I and II. Thus, in one preferred embodiment, ti>. stabilized., tablet. foπrnuat'on comprises an optimal disintegration agent, for example, crossprovidρne or -a disintegration agent more similar to polyvinylpyrrolidone than hydroxypropylcellulose. The preferred formulation is Formulation III. Other suitable tablet formulations may include at least ascorbic acid at a concentration of at least 0.01 % weight, or at least 0.05% weight or at least 0.1 % weight.
EXAMPLE 3
Three hundred mg tablets containing 100 mg tetrahydrobiopterin are prepared using the desired initial amount of polymorph B and mixing with other ingredients in the relative amounts shown below in Table III using the following dry tableting process. Tablets containing other desired amounts of tetrhydrobiopterin can be prepared in a similar manner.
The 6R-L-erythro-5, 6, 7, 8-tetrahydrobiopterin and D-Mannitol were hand screened with a 20 mesh screen (designed to filter out particles greater than ~850 μm in size) and placed in a blender. The mixture was blended for 10 minutes at 21 RPM. Next, the Anhydrous Dibasic Calcium Phosphate and CROSPO VIDONE were hand screened with a 20 mesh screen and blended with the BH4 and D-Mannitol for 10 minutes at 21 RPM. The Ascorbic Acid and Riboflavin were added to the blender after hand screening with a 20 mesh screen, and the resulting mixture blended for 10 minutes at 21 RPM. Next, the Sodium Stearyl Fumarate was added to the blender after hand screening with a 40 mesh screen, and blended for 5 minutes at 21 RPM. The blended mixture was then discharged into a bag and tested for uniformity, before being pressed into tablets.
Table III
_. t (wt %) (mg) Ingredient R-L-erythro-5, 6, 7, 8-tetrahydrobiopterin dihydrochloride salt 33.33 100.0
(Active Ingredient)
D-Mannitol
57.56 172.68 (Taste Masking)
Dibasic Calcium Phosphate, Anhydrous
2.18 6.54 (Binder)
CROSPOVIDONE
4.50 13.50 (Disintegration Agent)
Ascorbic acid
1.67 5.00 (Acidic Antioxidant)
Riboflavin
0.01 0.03 (Coloring Agent)
Stearyl Fumarate
0.75 2.25 (Lubricant)
The tablets were packaged either in foil blister-packs, or in HDPE bottles in quantities of 45-tablets per bottle. Each type of packaged tablets were divided into two batches. One batch was stored at room temperature, 25+2 0C, and 60+5% relative humidity. The other batch was stored under accelerated testing conditions, at 40+20C and 75+5% relative humidity. At regular intervals, tablets were removed from storage and tested for retention of the active pharmaceutical ingredient, 6R-L-erythro-5, 6, 7, 8-tetrahydrobiopterin. Exemplary results for the 300 mg tablets are shown below in Tables IV, V, VI and VII. After six months storage under room temperature or accelerated testing conditions, each of the four batches showed retention of at least 99% of the original amount of 6R-L-erγthro-5, 6, 7, 8- tetrahydrobiopterin by HPLC assay, loss on drying of less than 1%, and rapid disintegration in 3 minutes or less.
Table IV
SAPROPTERIN DIHYDROCHLORIDE DRUG PRODUCT
(300-MG TABLET, FOIL BLISTER-PACK) STORAGE CONDITIONS: 25 ± 2°C / 60 ± 5%RH
Figure imgf000033_0001
ND = None detected
Table V
SAPROPTERIN DIHYDROCHLORIDE DRUG PRODUCT
(300-MG TABLET, FOIL BLISTER-PACK) STORAGE CONDITIONS: 40 ± 20C / 75 ± 5 %RH
Figure imgf000034_0001
ND = None detected
Table VI
SAPROPTERIN DIHYDROCHLORIDE DRUG PRODUCT
(300-MG TABLET, 45 TABLET BOTTLES) STORAGE CONDITIONS: 25 ± 20C / 60 ± 5%RH
Figure imgf000035_0001
ND = None detected NT = Not tested NR = Not required
Table VII
SAPROPTERIN DIHYDROCHLORIDE DRUG PRODUCT
(300-MG TABLET, 45-TABLET BOTTLES) STORAGE CONDITIONS: 40 ± 20C / 75 ± 5 %RH
Figure imgf000036_0001
ND = None detected NT = Not tested NR = Not required

Claims

WHAT IS CLAIMED IS:
1. A stable tablet formulation comprising an initial amount of a crystalline polymorph, designated polymorph B, of (6R)-L-erythro- tetrahydrobiopterin and a pharmaceutically acceptable excipient, wherein after six months at room temperature and about 60% humidity the stable tablet formulation retains at least about 95% of the initial amount of (6R)-L-erythro-tetrahydrobiopterin, and wherein said crystalline polymorph, as a hydrochloride salt, exhibits an X-ray powder diffraction pattern with the following characteristic peaks expressed in d-values(A) : 8.7 (vs), 5.63 (m), 4.76(m), 4.40 (m), 4.00 (s), 3.23 (s), 3.11 (vs), preferably 8.7 (vs), 6.9 (w), 5.90 (vw), 5.63 (m), 5.07 (m), 4.76 (m), 4.40 (m), 4.15 (w), 4.00 (s), 3.95 (m), 3.52 (m), 3.44 (w), 3.32 (m), 3.23 (s), 3.17 (w), 3.11 (vs), 3.06 (w), 2.99 (w), 2.96 (w), 2.94 (m), 2.87 (w), 2.84 (s), 2.82 (m), 2.69 (w), 2.59 (w), and 2.44 (w).
2. The stable tablet formulation of claim 1, wherein after nine months at room temperature and about 60% humidity the stable tablet formulation retains at least about 95% of the initial amount of (6R)-L-erythro-tetrahydrobiopterin.
3. The stable tablet formulation of claim 1 or 2, wherein the stable tablet formulation retains at least about 98% of the initial amount of (6R)-L-erythro- tetrahydrobiopterin.
4. The stable tablet formulation of claim 1, wherein the initial amount of (6R)-L-erythro-tetrahydrobiopterin is in the range of about 30 wt% to about 40 wt% of the formulation.
5. The stable tablet formulation of claim 1, wherein the initial amount of (6R)-L-erythro-tetrahydrobiopterin is in the range of about 32 wt% to about 35 wt% of the formulation.
6. The stable tablet formulation of claim 1, wherein the initial amount of (6R)-L-erythro-tetrahydrobiopterin is in the range of about 33 wt%.
7. The stable tablet formulation of any of claims 1-5, wherein the initial amount of (6R)-L-erythro-tetrahydrobiopterin in each tablet is about 100 mg.
8. The stable tablet formulation of any of claims 1-5, wherein the initial amount of (6R)-L-erythro-tetrahydrobiopterin in each tablet is about 200 mg.
9. The stable tablet formulation of any of claims 1 -8, further comprising a binder.
10. The stable tablet formulation of claim 9, wherein the binder is anhydrous dibasic calcium phosphate.
11. The stable tablet formulation of any of claims 9-10, wherein the binder is in the range of about 1 wt% to about 5 wt%.
12. The stable tablet formulation of any of claims 9-10, wherein the binder is in the range of about 1.5 wt% to about 3 wt%.
13. The stable tablet formulation of any of claims 9-12, wherein the weight ratio of binder to tetrahydrobiopterin is in the range of about 1:10 to about 1 :20.
14. The stable tablet formulation of claim 13, wherein the weight ratio of binder to tetrahydrobiopterin is about 1 :15.
15. The stable tablet formulation of any of claims 1-14, further comprising a disintegration agent.
16. The stable table formulation of claim 15, wherein the disintegration agent is crospovidone.
17. The stable tablet formulation of any of claims 15-16, wherein the disintegration agent is in the range of about 3 wt% to about 10 wt%.
18. The stable tablet formulation of claim 17, wherein the disintegration agent is in the range of about 3 wt% to about 5 wt%.
19. The stable tablet formulation of any of claims 1-18, wherein the weight ratio of disintegration agent to tetrahydrobiopterin is in the range of about 1 :5 to about 1 :10.
20. The stable tablet formulation of claim 19, wherein the weight ratio of disintegration agent to tetrahydrobiopterin is about 1:7.5.
21. The stable tablet formulation of any of claims 1 -20, further comprising an acidic antioxidant.
22. The stable tablet formulation of claim 21 , wherein the acidic antioxidant is ascorbic acid.
23. The stable tablet formulation of any of claims 21 -22, wherein the acidic antioxidant is in the range of about 1 wt% to about 3 wt%.
24. The stable tablet formulation of any of claims 1 -23, wherein the weight ratio of acidic antioxidant to tetrahydrobiopterin is in the range of about 1:5 to 1:30.
25. The stable tablet formulation of claim 24, wherein the weight ratio of acidic antioxidant to tetrahydrobiopterin is about 1 :20.
26. The stable tablet formulation of any of claims 1-25, further comprising a lubricant.
27. The stable table formulation of claim 26, wherein the lubricant is stearyl fumarate.
28. The stable tablet formulation of any of claims 25-26, wherein the lubricant is in the range of about 0.1 wt% to about 2 wt%.
29. The stable tablet formulation of claim 28, wherein the lubricant is in the range of about 0.5 wt% to about 1 wt%.
30. The stable tablet formulation of any of claims 1 -29, wherein the weight ratio of lubricant to tetrahydrobiopterin is in the range of about 1:25 to 1:65.
31. The stable tablet formulation of claim 30, wherein the weight ratio of lubricant to tetrahydrobiopterin is about 1:45.
32. The stable tablet formulation of any of claims 1-31, further comprising vitamin B2 (riboflavin).
33. The stable tablet formulation of any of claims 1 -32, further comprising vitamin B 12.
34. The stable tablet formulation of any of claims 1-33, further comprising a folate.
35. The stable tablet formulation of any of claims 1 -34, further comprising arginine.
36. The stable tablet formulation of claim 34, wherein the folate is folic acid (pteroylmonoglutamate), dihydrofolic acid, tetrahydrofolic acid, 5- methyltetrahydrofolic acid, 5,10-methylenetetrahydrofolic acid, 5,10- methenyl tetrahydrofolic acid, 5,10-formiminotetrahydrofolic acid, 5- formyltetrahydrofolic acid (leucovorin), 10-formyltetrahydrofolic acid, 10- methyltetrahydrofolic acid, a folylpolyglutamates, a dihydrofolate, a tetrahydrofolates, 5-formyl-(6S)-tetrahydrofolic acid, 5-methyl-(6S)-tetrahydrofolic acid, 5,10-methylene-(6R)-tetrahydrofolic acid, 5,10-methenyl-(6R)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid, 5-formimino-(6S)-tetrahydrofolic acid or (6S)-tetrahydrofolic acid, or pharmaceutically acceptable salts thereof.
37. A stable tablet formulation of (6R)-L-erythro- tetrahydrobiopterin, comprising an initial amount of a crystalline polymorph of (6R)- L-erythro-tetrahydrobiopterin in the range of about 32 wt% to about 35 wt% of the formulation, crospovidone in the range of about 3 wt% to about 5 wt%, anhydrous dibasic calcium phosphate in the range of about 1.5 wt% to about 3 wt%, and stearyl fumarate in the range of about 0.5 wt% to about 1 wt%, wherein said stable tablet formulation has a shelf life at room temperature of at least 6 months, and wherein said crystalline polymorph, as a hydrochloride salt, exhibits an X-ray powder diffraction pattern with the following characteristic peaks expressed in d-values(A) : 8.7 (vs), 5.63 (m), 4.76(m), 4.40 (m), 4.00 (s), 3.23 (s), 3.11 (vs), preferably 8.7 (vs), 6.9 (w), 5.90 (vw), 5.63 (m), 5.07 (m), 4.76 (m), 4.40 (m), 4.15 (w), 4.00 (s), 3.95 (m), 3.52 (m), 3.44 (w), 3.32 (m), 3.23 (s), 3.17 (w), 3.11 (vs), 3.06 (w), 2.99 (w), 2.96 (w), 2.94 (m), 2.87 (w), 2.84 (s), 2.82 (m), 2.69 (w), 2.59 (w), and 2.44 (w).
38. The stable tablet formulation of claim 37 which has a shelf-life at room temperature of at least nine months.
39. The stable tablet formulation of claim 37 or 38 wherein the initial amount of said crystalline polymorph of (6R)-L-erythro-tetrahydrobiopterin is about 33 wt%, crospovidone is about 4.5 wt%, anhydrous dibasic calcium phosphate is about 2 wt%, and stearyl fumarate is about 0.75 wt%.
40. A method of making the stable tablet formulation of any one of claims 1-39 comprising the steps of mixing an initial amount of said crystalline polymorph of (6R)-L-erythro-tetrahydrobiopterin and one or more pharmaceutically acceptable excipients, and forming a tablet from the mixture, wherein the steps do not include adding liquid water.
41. The method of claim 40, wherein the one or more pharmaceutically acceptable excipients include a binder.
42. The method of claim 41 , wherein the binder is anhydrous dibasic calcium phosphate.
43. The method of any of claims 1 -42, wherein the one or more pharmaceutically acceptable excipients include a disintegration agent.
44. The method of claim 43, wherein the disintegration agent is crospovidone.
45. The method of any of claims 1 -44, wherein the one or more pharmaceutically acceptable excipients include an acidic antioxidant.
46. The method of claim 45, wherein the acidic antioxidant is ascorbic acid.
47. The method of any of claims 1 -46, wherein the one or more pharmaceutically acceptable excipients include a lubricant.
48. The method of claim 47, wherein the lubricant is formyl stearate.
PCT/US2005/041252 2004-11-17 2005-11-16 Stable tablet formulation of tetrahydrobiopterin WO2006055511A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP05822282A EP1845952A2 (en) 2004-11-17 2005-11-16 Stable tablet formulation of tetrahydrobiopterin
BRPI0517088-5A BRPI0517088A (en) 2004-11-17 2005-11-16 stable tablet formulation
US10/563,418 US8003126B2 (en) 2004-11-17 2005-11-16 Stable tablet formulation
AU2005306686A AU2005306686B2 (en) 2004-11-17 2005-11-16 Stable tablet formulation of tetrahydrobiopterin
JP2007541419A JP2008520574A (en) 2004-11-17 2005-11-16 Tetrahydrobiopterin stable tablet formulation
MX2007005039A MX2007005039A (en) 2004-11-17 2005-11-16 Stable tablet formulation of tetrahydrobiopterin.
CA2581814A CA2581814C (en) 2004-11-17 2005-11-16 Stable tablet formulation of tetrahydrobiopterin
IL182161A IL182161A (en) 2004-11-17 2007-03-25 Stable formulation comprising a crystalline polymorph of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
US12/106,621 US7566462B2 (en) 2004-11-17 2008-04-21 Stable tablet formulation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62918904P 2004-11-17 2004-11-17
US60/629,189 2004-11-17

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/563,418 A-371-Of-International US8003126B2 (en) 2004-11-17 2005-11-16 Stable tablet formulation
US12/106,621 Continuation US7566462B2 (en) 2004-11-17 2008-04-21 Stable tablet formulation

Publications (2)

Publication Number Publication Date
WO2006055511A2 true WO2006055511A2 (en) 2006-05-26
WO2006055511A3 WO2006055511A3 (en) 2006-10-05

Family

ID=35849290

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/041252 WO2006055511A2 (en) 2004-11-17 2005-11-16 Stable tablet formulation of tetrahydrobiopterin

Country Status (15)

Country Link
US (2) US8003126B2 (en)
EP (2) EP2436379A1 (en)
JP (2) JP2008520574A (en)
KR (1) KR20070084270A (en)
CN (1) CN101132776A (en)
AR (1) AR052238A1 (en)
AU (1) AU2005306686B2 (en)
BR (1) BRPI0517088A (en)
CA (1) CA2581814C (en)
IL (1) IL182161A (en)
MX (1) MX2007005039A (en)
MY (1) MY142120A (en)
PE (1) PE20061294A1 (en)
TW (1) TW200624120A (en)
WO (1) WO2006055511A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008089148A1 (en) * 2007-01-12 2008-07-24 Biomarin Pharmaceutical Inc. Method of treating a metabolic or neuropsychiatry disorder with a bh4 derivative prodrug
WO2008128049A2 (en) 2007-04-11 2008-10-23 Biomarin Pharmaceutical Inc. Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
JP2010526140A (en) * 2007-05-03 2010-07-29 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー New pharmaceutical composition
WO2012117362A1 (en) * 2011-03-01 2012-09-07 Rubicon Research Private Limited Stable compositions of tetrahydrobiopterin
EP2926805A1 (en) * 2014-03-31 2015-10-07 Vasopharm GmbH Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
US9433624B2 (en) 2003-11-17 2016-09-06 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of metabolic disorders
US9572870B2 (en) 2003-08-29 2017-02-21 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
EP4034126A4 (en) * 2019-09-23 2023-10-18 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical formulations comprising sapropterin dihydrochloride and at least one antioxidant

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005239939C1 (en) * 2004-05-11 2011-06-30 Daiichi Sankyo Company Limited BH4-responsive hyperphenylalaninemia remedies
CN101132776A (en) 2004-11-17 2008-02-27 生物马林药物股份有限公司 Stable tablet formulation of tetrahydrobiopterin
JP2010515747A (en) * 2007-01-12 2010-05-13 ビオマリン プハルマセウトイカル インコーポレイテッド Tetrahydrobiopterin prodrug
AU2008347005B2 (en) * 2008-01-03 2013-10-03 Biomarin Pharmaceutical Inc. Pterin analog for treating BH4 responsive condition
TR201910287T4 (en) * 2008-08-12 2019-07-22 Orpha Swiss Gmbh Pharmaceutical dosage form containing tetrahydrobiopterin.
WO2012127431A1 (en) * 2011-03-24 2012-09-27 Rubicon Research Private Limited Stabilized compositions of tetrahydrobiopterin
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
CN102775408B (en) * 2012-01-20 2015-09-02 连云港金康医药科技有限公司 Stable 5-methyltetrahydrofolate crystal formation and preparation method thereof
CN104530051B (en) * 2012-01-20 2016-08-24 连云港金康和信药业有限公司 Stable (6R, S)-5-methyltetrahydrofolate crystal formation and preparation method thereof
WO2017106130A1 (en) * 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Process for preparing pharmaceutical compositions
MX2018007112A (en) * 2015-12-18 2018-09-07 Colgate Palmolive Co Fast dissolving peroxymonosulfate composition.
EP3491008A2 (en) 2016-07-26 2019-06-05 BioMarin Pharmaceutical Inc. Novel adeno-associated virus capsid proteins
US20190167598A1 (en) 2016-07-29 2019-06-06 Dipharma S.A. A novel treatment regimen involving sapropterin dihydrochloride
US20180110781A1 (en) * 2016-10-24 2018-04-26 Research Foundation For Mental Hygiene, Inc. System and method for diagnosis and treatment of neuropsychiatric disorders
US10758462B2 (en) * 2016-11-16 2020-09-01 Colgate-Palmolive Company Oral care composition
CN110312721A (en) 2016-11-29 2019-10-08 显莎制药公司 The polymorph of sepiapterin
MX2019006206A (en) * 2016-11-29 2019-08-14 Censa Pharmaceuticals Inc Polymorphs of sepiapterin and salts thereof.
WO2019046849A1 (en) * 2017-09-01 2019-03-07 Censa Pharmaceuticals Inc. Pharmaceutical compositions comprising sepiapterin and uses thereof
KR20210008501A (en) 2018-05-09 2021-01-22 바이오마린 파머수티컬 인크. How to treat phenylketonuria
TW202005978A (en) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 Novel liver targeting adeno-associated viral vectors
LT3801536T (en) 2018-05-30 2024-09-25 Ptc Therapeutics Mp, Inc. Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
TR201914416A1 (en) 2019-09-23 2021-04-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Effervescent formulations of sapropterin dihydrochloride
TR201914406A2 (en) * 2019-09-23 2021-04-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi SOLID ORAL PHARMACEUTICAL FORMULATIONS CONTAINING SAPROPTERIN DIHYDROCHLORIDE AND AT LEAST ONE PHARMACEUTICAL EXCIPIENT
TW202144575A (en) 2020-04-03 2021-12-01 美商拜奧馬林製藥公司 Treatment of phenylketonuria with aav and therapeutic formulations
CN117205164B (en) * 2023-09-30 2024-07-26 山东新时代药业有限公司 Sapropterin hydrochloride tablet and preparation method thereof

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2603643A (en) 1947-03-13 1952-07-15 Hoffmann La Roche 2-amino-4-hydroxy-6-polyhydroxyalkyl pteridine and methods of oxidizing same
US2601215A (en) 1948-03-17 1952-06-17 American Cyanamid Co Process of preparing dihydropterins
US2541717A (en) 1948-10-18 1951-02-13 Upjohn Co Pterine imines
US2568685A (en) 1950-07-22 1951-09-18 Upjohn Co 2-amino-4-hydroxy-6-omega-carboxytrihydroxy-propylpteridines
US2955110A (en) 1955-01-13 1960-10-04 American Cyanamid Co Substituted pteridines and method of preparing the same
US3505329A (en) 1968-02-06 1970-04-07 Smithkline Corp Process for the synthesis of biopterin
GB2056459B (en) 1979-07-04 1983-03-09 Daiichi Radioisotope Lab Pterin derivatives and an assay method for determining pterins
US4252822A (en) 1979-12-26 1981-02-24 Children's Hospital Medical Center Method for treating phenylketonuria
JPS5883691A (en) 1981-11-13 1983-05-19 Kanegafuchi Chem Ind Co Ltd 1',2'-diacyl-(6r,s)-5,6,7,8-tetrahydro-l-biopterin and its preparation
JPS5925323A (en) 1982-03-03 1984-02-09 鐘淵化学工業株式会社 Depression disease parkinsonism therapy made from pterin derivative
JPS5921685A (en) 1982-07-28 1984-02-03 Suntory Ltd Preparation of tetrahydro-l-biopterin
AU572792B2 (en) 1982-09-20 1988-05-19 Wellcome Foundation Limited, The 2-amino, 4-oxo-pteridine derivatives
GB8318833D0 (en) 1983-07-12 1983-08-10 Wellcome Found Chemical compounds
ZA836957B (en) 1982-09-20 1985-04-24 Wellcome Found Neurologically active chemical compounds
US5196533A (en) 1983-04-11 1993-03-23 South Alabama Medical Science Foundation, Usa Cyclization of 5 amino-pyrimidines to quinoid 6,6 disubstituted dihydropteridines
US4587340A (en) 1983-09-19 1986-05-06 Burroughs Wellcome Co. Biopterin analogs
JPS60178887A (en) 1984-02-23 1985-09-12 Kanegafuchi Chem Ind Co Ltd Preparation of 5,6,7,8-tetrahydro-l-biopterin
JPS60199889A (en) 1984-03-24 1985-10-09 Kanegafuchi Chem Ind Co Ltd 5,6,7,8-tetrahydro-l-erythro-biopterin sulfate and its preparation
US4550109A (en) 1984-05-31 1985-10-29 The Board Of Regents, The University Of Texas System Lipoidal biopterin compounds
DE3437944A1 (en) 1984-10-17 1986-07-31 Biotest-Serum-Institut Gmbh, 6000 Frankfurt USE OF PTERINES TO INCREASE THE ACTIVITY OF LYMPHOKINES AND OTHER BLOOD FACTORS, AND A DIAGNOSTIC OR THERAPEUTIC PREPARATION CONTAINING PTERINE IN COMBINATION WITH LYMPHOKINES
US4713454A (en) 1985-01-28 1987-12-15 Shiratori Pharmaceutical Co., Ltd. Preparation process of (6R)-tetrahydro-L-biopterin
JPS61172877A (en) * 1985-01-28 1986-08-04 Shiratori Seiyaku Kk Production of (6r)-tetrahydro-l-biopterin
JPS61277618A (en) 1985-06-04 1986-12-08 Suntory Ltd Remedy for autism
ATE66147T1 (en) 1987-02-13 1991-08-15 Allergan Pharma USE OF PTERIDINES AND/OR PURINES OR AN INHIBITOR OF XANTHINOXIDASE IN THE MANUFACTURE OF A MEDICATION FOR THE TREATMENT OF GENETIC DEGENERATING RETINAL DISEASES.
JP2588191B2 (en) * 1987-04-24 1997-03-05 サントリー株式会社 Therapeutic agent for improving neurological symptoms associated with malignant tumors and severe viral infections
DE3853711T2 (en) 1987-11-30 1996-01-11 Vitamin Kenkyusho Kk Intermediates for the synthesis of 5,6,7,8-tetrahydro-L-erythro-biopterin and its derivatives.
EP0349204A3 (en) 1988-06-28 1991-08-07 Bend Research, Inc. Use and regeneration of reagents using coupled reactions and permselective barriers
JP2843592B2 (en) 1989-02-28 1999-01-06 日清製粉株式会社 L-ribose derivative
US5554647A (en) 1989-10-12 1996-09-10 Perricone; Nicholas V. Method and compositions for treatment and/or prevention of skin damage and aging
WO1991012814A1 (en) 1990-02-28 1991-09-05 E.I. Du Pont De Nemours And Company Activation of monocyte/macrophages
JP3137333B2 (en) 1990-07-21 2001-02-19 サントリー株式会社 Method for producing tetrahydrobiopterin and enzyme used therefor
DE4037447C2 (en) 1990-11-24 1994-06-01 Milupa Ag Phenylalanine-free dietetic for juvenile and adult individuals with phenylketonuria and a method for its production
JPH04210624A (en) 1990-12-11 1992-07-31 Shigenobu Sakata Bathing agent and lotion having medicinal effect
WO1993010155A1 (en) 1991-11-16 1993-05-27 Suntory Limited 6(r)-l-erythro-5,6,7,8-tetrahydrobiopterin receptor
US5877176A (en) 1991-12-26 1999-03-02 Cornell Research Foundation, Inc. Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis
JP2534423B2 (en) 1991-12-26 1996-09-18 コーネル・リサーチ・ファンデーション・インコーポレイテッド Inhibitors that prevent vascular disorders resulting from overproduction of nitric oxide
US5198547A (en) 1992-03-16 1993-03-30 South Alabama Medical Science Foundation, Usa Process for N5-formylating tetrahydropteridines
DE4215275A1 (en) 1992-05-09 1993-11-11 Merck Patent Gmbh Means and methods for the treatment of body fluids in the determination of neopterin
US6251953B1 (en) 1992-10-30 2001-06-26 Andrew Brookner Beta-carotene therapy of individuals having abnormal immunological and serological indices, and individuals having infections and diseases causing changes therein
US5658565A (en) 1994-06-24 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Inducible nitric oxide synthase gene for treatment of disease
WO1994012645A2 (en) 1992-11-25 1994-06-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education cDNA CLONE FOR HUMAN INDUCIBLE NITRIC OXYDE SYNTHASE AND PROCESS FOR PREPARING SAME
US5830461A (en) 1992-11-25 1998-11-03 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods for promoting wound healing and treating transplant-associated vasculopathy
US20020061862A1 (en) 1992-11-25 2002-05-23 University Of Pittsburgh Of The Commonwealth System Of Higher Education Inducible nitric oxide synthase for treatment of disease
US5468772A (en) 1993-03-10 1995-11-21 Pharmagenesis, Inc. Tripterinin compound and method
DE4308739C1 (en) 1993-03-19 1994-06-23 Henning Berlin Gmbh Pterin derivatives, their preparation and their use
CA2157758A1 (en) 1993-03-19 1994-09-29 Louis Chedid Compositions for use in human therapeutics, characterised by the association of a muramyl peptide with a cytokine
US5449688A (en) 1993-03-30 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Method of treating chronic inflammatory diseases
US5945452A (en) 1993-06-11 1999-08-31 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity
US5502050A (en) 1993-11-29 1996-03-26 Cornell Research Foundation, Inc. Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis
TW282398B (en) 1993-12-22 1996-08-01 Bristol Myers Squibb Co
JP3347870B2 (en) * 1994-04-15 2002-11-20 三菱電機株式会社 Superconducting magnet and regenerative refrigerator for the magnet
DE4418096A1 (en) 1994-05-24 1995-11-30 Cassella Ag Use of pteridine derivatives as inhibitors of NO synthase
ES2177654T3 (en) 1994-08-05 2002-12-16 Suntory Ltd REMEDY AGAINST SPINOCEREBELUS DEGENERATION.
US5643586A (en) 1995-04-27 1997-07-01 Perricone; Nicholas V. Topical compositions and methods for treatment of skin damage and aging using catecholamines and related compounds
US5744340A (en) 1995-06-09 1998-04-28 Schering Corporation Expression of human inducible nitric oxide synthase
SE506533C2 (en) 1995-07-03 1998-01-12 Birger Andersson A process for in vitro analysis of the toxic and allergenic properties of substances and the use of neopterin to distinguish between allergic immune reactions
US5879690A (en) 1995-09-07 1999-03-09 Perricone; Nicholas V. Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers
JP2711828B2 (en) 1996-06-25 1998-02-10 白鳥製薬株式会社 Method for producing (6R) -tetrahydro-L-biopterin hydrochloride
US20020076782A1 (en) 1996-07-05 2002-06-20 John P.N. Rosazza Purified nitric oxide synthase
US5856158A (en) 1996-07-05 1999-01-05 University Of Iowa Research Foundation Purified nitric oxide synthase from rat brain
ATE295847T1 (en) 1996-07-31 2005-06-15 Cmic Co Ltd PTERINE DERIVATIVES CONTAINING ACTIVE OXYGEN SUPPORTERS
GB9617990D0 (en) 1996-08-29 1996-10-09 Scotia Holdings Plc Treatment of pain
KR20060094988A (en) 1996-08-30 2006-08-30 다이이치 아스비오파마 가부시키가이샤 Preventives or remedies for diseases induced by hypofunction of nitric oxide synthase (nos)
AU6237798A (en) 1996-12-24 1998-07-17 Research Development Foundation Ricin inhibitors and methods for use thereof
US6562969B1 (en) 1996-12-24 2003-05-13 Research Development Foundation Ricin inhibitors and methods for use thereof
US6428990B1 (en) 1997-04-11 2002-08-06 Abbott Laboratories Human desaturase gene and uses thereof
US5846775A (en) 1997-04-22 1998-12-08 Incyte Pharmaceuticals, Inc. GTP cyclohydrolase I regulatory protein
CH693255A5 (en) 1997-06-13 2003-05-15 Eprova Ag Use of tetrahydrofolates natürlichenstereoisomeren in the form suitable for the preparation of a pharmaceutical composition for influencing the homocysteine ​​level.
US5922713A (en) 1997-06-26 1999-07-13 Werner; Ernst Inhibition of nitric oxide synthase
ATE201412T1 (en) 1997-10-06 2001-06-15 Ernst Werner PTERIDINE DERIVATIVES AS NO SYNTHASE INHIBITORS
WO1999018958A1 (en) 1997-10-15 1999-04-22 Uab Research Foundation Bathocuproine treatment of neurologic disease
JP4486167B2 (en) 1998-02-27 2010-06-23 アスビオファーマ株式会社 Preventive or therapeutic agent for drug-induced renal injury
JP4306825B2 (en) 1998-02-27 2009-08-05 アスビオファーマ株式会社 Preventive or therapeutic agent for diseases associated with vascular dysfunction involving insulin resistance
US6180597B1 (en) 1998-03-19 2001-01-30 Brigham And Women's Hospital, Inc. Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
US6162914A (en) 1998-04-24 2000-12-19 Cerbios-Pharma S.A. Process for the reduction of pterins
US6117872A (en) 1998-06-23 2000-09-12 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of exercise performance by augmenting endogenous nitric oxide production or activity
US6423751B1 (en) 1998-07-14 2002-07-23 The Brigham And Women's Hospital, Inc. Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
US6346519B1 (en) 1998-09-09 2002-02-12 Advanced Medical Instruments Method and composition for treating arthritis
US6656925B2 (en) 1998-09-09 2003-12-02 Advanced Medical Instruments Composition and method of treating arthritis
US7276506B2 (en) 1998-12-28 2007-10-02 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
US6319905B1 (en) 1998-12-29 2001-11-20 Cell Genesys, Inc. Method of controlling L-Dopa production and of treating dopamine deficiency
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
EP1140091B1 (en) 1999-01-08 2005-09-21 3M Innovative Properties Company Formulations comprising imiquimod or other immune response modifiers for treating cervical dysplasia
US6200758B1 (en) 1999-02-19 2001-03-13 New York State Office Of Mental Health Phenylalanine hydroxylase gene variants, and amino acid and pterin homeostasis, in the definition, detection, treatment and prevention of psychotic, mood and personality disorders
AU4013900A (en) 1999-03-19 2000-10-09 Enos Pharmaceuticals, Inc. Increasing cerebral bioavailability of drugs
US6288535B1 (en) 1999-07-06 2001-09-11 Jacob Chass Hall effect, shaft angular position sensor with asymmetrical rotor
CA2380072C (en) 1999-07-28 2007-07-10 John Cooke Nicotine in therapeutic angiogenesis and vasculogenesis
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
US20020155445A1 (en) 1999-12-16 2002-10-24 Jarvik Jonathan W. Methods and products for peptide based DNA sequence identification and analysis
AUPQ598300A0 (en) 2000-03-03 2000-03-23 Citrus Sensation Pty Ltd Citrus fruit preservative
US6576105B1 (en) 2000-03-31 2003-06-10 Truman State University Pteridine analysis by capillary electrophoresis using laser-induced fluorescence detection
US6784178B2 (en) 2000-04-12 2004-08-31 Cornell Research Foundation, Inc. Pharmacotherapy for vascular dysfunction associated with deficient nitric oxide bioactivity
US6544994B2 (en) 2000-06-07 2003-04-08 Eprov Ag Pharmaceutical preparation for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase
US20030124524A1 (en) 2000-06-23 2003-07-03 Kenneth Kornman Screening assays for identifying modulators of the inflammatory or immune response
US6660831B2 (en) 2000-08-14 2003-12-09 Joan M. Fallon Method for diagnosing and treating dysautonomia and other dysautonomic conditions
KR100916163B1 (en) 2000-08-31 2009-09-08 아스비오파마 가부시키가이샤 Process for producing biopterins
DE10043845A1 (en) 2000-09-06 2002-03-14 Gruenenthal Gmbh Method of measuring NO synthase activity
US6689385B2 (en) 2000-11-03 2004-02-10 Chronorx Llc Formulations for the treatment of insulin resistance and type 2 diabetes mellitus
UA80393C2 (en) 2000-12-07 2007-09-25 Алтана Фарма Аг Pharmaceutical preparation comprising an pde inhibitor dispersed on a matrix
US6537992B2 (en) 2001-01-05 2003-03-25 John D. Parker Regulation of organic nitrate tolerance
TWI241190B (en) 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
US6693094B2 (en) 2001-03-22 2004-02-17 Chrono Rx Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
US6500857B1 (en) 2001-08-16 2002-12-31 Nicholas V. Perricone Subcutaneous muscle treatment using electronic stimulation and topical compositions
US20030078231A1 (en) 2001-06-22 2003-04-24 Wilburn Michael D. Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties
US20030004125A1 (en) 2001-06-22 2003-01-02 Hirst David G. Inducible gene
US6787178B2 (en) * 2001-07-09 2004-09-07 Kiyoshi Yamamoto Health drink and method for production thereof
JP4082888B2 (en) 2001-10-17 2008-04-30 広栄化学工業株式会社 Process for producing biaryl compounds
CH696628A5 (en) * 2002-02-26 2007-08-31 Eprova Ag Use of folate suitable for the manufacture of a preparation for the prevention and treatment of inflammation and inflammation-associated diseases, in particular for influencing the
DE10260263A1 (en) 2002-12-20 2004-07-15 Biocrates Life Sciences Gmbh Use of tetrahydrobiopterin derivatives for the treatment and nutrition of patients with amino acid metabolism disorders
US20070167353A1 (en) 2003-10-24 2007-07-19 John Hilfinger Prodrug composition
US20050137141A1 (en) 2003-10-24 2005-06-23 John Hilfinger Prodrug composition
CA2678124C (en) * 2003-11-17 2014-10-07 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
EP1708690B1 (en) 2003-11-17 2016-07-20 BioMarin Pharmaceutical Inc. Treatment of phenylketonuria with bh4
US7732599B2 (en) 2003-11-17 2010-06-08 Biomarin Pharmaceutical Inc. Process for preparing tetrahydrobiopterin and analogs of tetrahydrobiopterin
US7067659B2 (en) 2004-04-23 2006-06-27 Duke University Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof
AU2005239939C1 (en) 2004-05-11 2011-06-30 Daiichi Sankyo Company Limited BH4-responsive hyperphenylalaninemia remedies
CA2601716C (en) 2004-06-25 2011-05-31 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia
CN101132776A (en) 2004-11-17 2008-02-27 生物马林药物股份有限公司 Stable tablet formulation of tetrahydrobiopterin
US20100130500A1 (en) 2004-12-08 2010-05-27 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
US20060194808A1 (en) 2005-01-14 2006-08-31 Chronorx Llc, An Alaska Limited Liability Company Clinical applications of tetrahydrobiopterin, lipoic acid and their salts and methods of preparing tetrahydrobiopterin bis-lipoate
JP2009518415A (en) 2005-12-05 2009-05-07 バイオマリン ファーマシューティカル インコーポレイテッド Methods and compositions for treatment of disease
EP1964566A4 (en) 2005-12-22 2009-01-07 Asubio Pharma Co Ltd Preparation with improved bioabsorbability of sapropterin hydrochloride
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
ES2732293T3 (en) 2007-02-22 2019-11-21 Childrens Hospital & Res Center At Oakland Fatty acid formulations and methods for using them
JP5226960B2 (en) * 2007-02-28 2013-07-03 株式会社スクウェア・エニックス GAME DEVICE, VIRTUAL CAMERA CONTROL METHOD, PROGRAM, AND RECORDING MEDIUM

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1845952A2 *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040088B2 (en) 2003-08-29 2021-06-22 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US9572870B2 (en) 2003-08-29 2017-02-21 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US9993481B2 (en) 2003-11-17 2018-06-12 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of metabolic disorders
US9433624B2 (en) 2003-11-17 2016-09-06 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of metabolic disorders
WO2008089148A1 (en) * 2007-01-12 2008-07-24 Biomarin Pharmaceutical Inc. Method of treating a metabolic or neuropsychiatry disorder with a bh4 derivative prodrug
WO2008128049A2 (en) 2007-04-11 2008-10-23 Biomarin Pharmaceutical Inc. Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
AU2008240259C1 (en) * 2007-04-11 2022-11-24 Biomarin Pharmaceutical Inc. Tetrahydrobiopterin compositions and methods of measuring
EP4029519A1 (en) 2007-04-11 2022-07-20 BioMarin Pharmaceutical Inc. Tetrahydrobiopterin for treating conditions associated with elevated phenylalanine levels
EP2545939A2 (en) 2007-04-11 2013-01-16 BioMarin Pharmaceutical Inc. Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
EP3461503B1 (en) 2007-04-11 2022-02-09 BioMarin Pharmaceutical Inc. Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
EP2545939B1 (en) 2007-04-11 2020-12-16 BioMarin Pharmaceutical Inc. Tetrahydrobiopterin for treating conditions associated with elevated phenylalanine levels
EP3461503A1 (en) 2007-04-11 2019-04-03 BioMarin Pharmaceutical Inc. Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
KR101475971B1 (en) * 2007-05-03 2014-12-23 글락소스미스클라인 엘엘씨 Novel pharmaceutical composition
JP2010526140A (en) * 2007-05-03 2010-07-29 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー New pharmaceutical composition
US9492451B2 (en) 2011-03-01 2016-11-15 Dipharma S.A. Stable compositions of tetrahydrobiopterin
CN103458900A (en) * 2011-03-01 2013-12-18 鲁必康研究私人有限公司 Stable compositions of tetrahydrobiopterin
WO2012117362A1 (en) * 2011-03-01 2012-09-07 Rubicon Research Private Limited Stable compositions of tetrahydrobiopterin
US10016431B2 (en) 2014-03-31 2018-07-10 Vasopharm Gmbh Solid pharmaceutical compositions comprising biopterin derivatives and uses of suchcompositions
RU2694368C2 (en) * 2014-03-31 2019-07-12 ВАЗОФАРМ ГмбХ Solid pharmaceutical compositions containing biopterin derivatives, and methods of using such compositions
US10493075B2 (en) 2014-03-31 2019-12-03 Vasopharm Gmbh Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
WO2015150294A1 (en) 2014-03-31 2015-10-08 Vasopharm Gmbh Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
US10925877B2 (en) 2014-03-31 2021-02-23 Vasopharm Gmbh Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
EP2926805A1 (en) * 2014-03-31 2015-10-07 Vasopharm GmbH Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
US11717522B2 (en) 2014-03-31 2023-08-08 Vasopharm Gmbh Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
EP4034126A4 (en) * 2019-09-23 2023-10-18 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical formulations comprising sapropterin dihydrochloride and at least one antioxidant

Also Published As

Publication number Publication date
CA2581814C (en) 2015-10-13
US7566462B2 (en) 2009-07-28
EP1845952A2 (en) 2007-10-24
MY142120A (en) 2010-09-15
CN101132776A (en) 2008-02-27
IL182161A0 (en) 2007-07-24
AU2005306686B2 (en) 2011-06-02
US8003126B2 (en) 2011-08-23
BRPI0517088A (en) 2008-09-30
JP2008520574A (en) 2008-06-19
PE20061294A1 (en) 2006-12-18
KR20070084270A (en) 2007-08-24
EP2436379A1 (en) 2012-04-04
US20080207626A1 (en) 2008-08-28
JP2014012740A (en) 2014-01-23
MX2007005039A (en) 2007-06-19
AU2005306686A1 (en) 2006-05-26
AR052238A1 (en) 2007-03-07
CA2581814A1 (en) 2006-05-26
US20070270581A1 (en) 2007-11-22
TW200624120A (en) 2006-07-16
IL182161A (en) 2011-08-31
WO2006055511A3 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
US8003126B2 (en) Stable tablet formulation
US9993481B2 (en) Methods and compositions for the treatment of metabolic disorders
US20190160070A1 (en) Dry blend formulation of tetrahydrobiopterin
AU2008240259C1 (en) Tetrahydrobiopterin compositions and methods of measuring
BAKER Patent 2545584 Summary

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200580038910.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005306686

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2581814

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 182161

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2764/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005822282

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005306686

Country of ref document: AU

Date of ref document: 20051116

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005306686

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/005039

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007541419

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020077011104

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 10563418

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2005822282

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10563418

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0517088

Country of ref document: BR